1,375 results on '"KOYANAGI, A."'
Search Results
2. Intrahepatic cholangiocarcinoma with arterial phase hyperenhancement and specialized tumor microenvironment associated with good prognosis after radical resection: A single-center retrospective study.
- Author
-
Mashiko, Taro, Carreras, Joaquim, Ogasawara, Toshihito, Masuoka, Yoshihito, Ei, Shigenori, Takahashi, Shinichiro, Nomura, Takakiyo, Mori, Masaki, Koyanagi, Kazuo, Yamamoto, Seiichiro, Nakamura, Naoya, and Nakagohri, Toshio
- Abstract
This single-center retrospective study aimed to clarify the clinical and pathologic background of mass-forming intrahepatic cholangiocarcinomas. A total of 53 patients with mass-forming intrahepatic cholangiocarcinomas were selected from 2007 to 2021 and analyzed based on several parameters, including the preoperative computed tomography pattern (enhancement in the arterial phase of dynamic contrast-enhanced computed tomography), clinical data, and tumor microenvironment evaluated by immunohistochemistry. The hyperenhancement (n = 13) and hypoenhancement (n = 40) groups were defined using the 50% cutoff of tumors with higher attenuation than the liver parenchyma. The hyperenhancement group was characterized by a better overall survival than the hypoenhancement group (5-year survival: 86% vs 27%, respectively; P <.001) and by a higher infiltration of peritumoral (92% vs 58%; P =.020) and intratumoral CD3-positive T lymphocytes (85% vs 35%; P =.002). Conversely, the hypoenhancement group was characterized by a higher infiltration versus peritumoral CD163-positive tumor-associated macrophages (60% vs 8%; P =.001), peritumoral pentraxin 3–positive tumor-associated macrophages (50% vs 15%; P =.024), and intratumoral α–smooth muscle actin–positive cancer-associated fibroblasts (15% vs 68%; P =.001). A multiple regression analysis was performed to predict overall survival from the microenvironment, and the independent poor predictor factors were low intratumoral CD3-positive T lymphocytes (hazard ratio = 2.75), high peritumoral (hazard ratio = 2.38), and intratumoral CD163-positive tumor-associated macrophages (hazard ratio = 2.81) (all P values < 0.05). Compared with hypovascular, hypervascular mass-forming intrahepatic cholangiocarcinomas have better tumor immunity and prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
- Author
-
Solmi, Marco, Miola, Alessandro, Capone, Federico, Pallottino, Simone, Højlund, Mikkel, Firth, Joseph, Siskind, Dan, Holt, Richard I. G., Corbeil, Olivier, Cortese, Samuele, Dragioti, Elena, Du Rietz, Ebba, Nielsen, René Ernst, Nordentoft, Merete, Fusar-Poli, Paolo, Hartman, Catharina A., Høye, Anne, Koyanagi, Ai, Larsson, Henrik, Lehto, Kelli, Lindgren, Peter, Manchia, Mirko, Skonieczna-Żydecka, Karolina, Stubbs, Brendon, Vancampfort, Davy, Vieta, Eduard, Taipale, Heidi, and Correll, Christoph U.
- Abstract
ABSTRACTIntroductionPeople with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.Areas coveredWe searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.Expert opinionTo prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications’ and patient’s weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.
- Published
- 2024
- Full Text
- View/download PDF
4. Evaluation of HER2 immunohistochemistry-positive and immunohistochemistry-negative FISH amplification breast cancers using next-generation sequencing
- Author
-
Baba, Shogo, Koyanagi, Ai, Kakumoto, Akinari, Kuroda, Hajime, Harada, Oi, Suzuki, Megumi, Kato, Yasutaka, Nishihara, Hiroshi, and Kawami, Hiroyuki
- Published
- 2024
- Full Text
- View/download PDF
5. Japanese-Canadian Educators During the Internment Years.
- Author
-
Koyanagi, Megan
- Published
- 2024
6. Slow gut transit increases the risk of Alzheimer's disease: An integrated study of the bi-national cohort in South Korea and Japan and Alzheimer's disease model mice.
- Author
-
Kang, Jiseung, Lee, Myeongcheol, Park, Mincheol, Lee, Jibeom, Lee, Sunjae, Park, Jaeyu, Koyanagi, Ai, Smith, Lee, Nehs, Christa J., Yon, Dong Keon, and Kim, Tae
- Abstract
[Display omitted] • Constipation was associated with an increased risk of Alzheimer's disease (AD) in the South Korean cohort (discovery cohort, HR, 2.04; 95% CI, 2.01–2.07) and the Japan cohort (validation cohort, HR, 2.82; 95% CI, 2.61–3.05). • Loperamide-treated AD mouse model showed increased amyloid-beta and microglia in the brain with slow gut transit. • Loperamide-treated AD mouse model had increased transcription of genes related to norepinephrine secretion and immune responses and decreased transcription of defense against bacteria in colonic tissue. Although the association between Alzheimer's disease (AD) and constipation is controversial, its causality and underlying mechanisms remain unknown. To investigate the potential association between slow gut transit and AD using epidemiological data and a murine model. We conducted a bi-national cohort study in South Korea (discovery cohort, N=3,130,193) and Japan (validation cohort, N=4,379,285) during the pre-observation period to determine the previous diagnostic history (2009–2010) and the follow-up period (2011–2021). To evaluate the causality, we induced slow gut transit using loperamide in 5xFAD transgenic mice. Changes in amyloid-beta (Aβ) and other markers were examined using ELISA, qRT-PCR, RNA-seq, and behavioral tests. Constipation was associated with an increased risk of AD in the discovery cohort (hazard ratio, 2.04; 95% confidence interval [CI], 2.01–2.07) and the validation cohort (hazard ratio; 2.82; 95% CI, 2.61–3.05). We found that loperamide induced slower gut transit in 5xFAD mice, increased Aβ and microglia levels in the brain, increased transcription of genes related to norepinephrine secretion and immune responses, and decreased the transcription of defense against bacteria in the colonic tissue. Impaired gut transit may contribute to AD pathogenesis via the gut-brain axis, thus suggesting a cyclical relationship between intestinal barrier disruption and Aβ accumulation in the brain. We propose that gut transit or motility may be a modifiable lifestyle factor in the prevention of AD, and further clinical investigations are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.
- Author
-
Watanabe, Shinya, Nonaka, Takahiro, Maeda, Makoto, Yamada, Masanobu, Sugii, Narushi, Hashimoto, Koichi, Takano, Shingo, Koyanagi, Tomoyoshi, Arakawa, Yoshihiro, and Ishikawa, Eiichi
- Subjects
RESEARCH funding ,CLINICAL trials ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,RESEARCH ,BIOLOGICAL assay ,COMPARATIVE studies ,PROGRESSION-free survival ,BRAIN tumors ,OVERALL survival - Abstract
Background: Appropriate exploratory efficacy data from Phase I trials are vital for subsequent phases. Owing to the uniqueness of brain tumors (BTs), use of different strategies to evaluate efficacy is warranted. We studied exploratory efficacy evaluation in Phase I trials involving BTs. Methods: Using Clarivate's Cortellis
™ , 42 Phase I trials of BT interventions conducted from 2020 to 2022 were analyzed for efficacy endpoints, which were set as primary endpoints (PEs) or secondary endpoints (SEs). Additionally, these metrics were compared in two subgroups: trials including only BTs (Group-A) and those including BTs among mixed solid tumors (Group-B). Results: Selected studies included a median of 1.5 PEs (range, 1–6) and 5 SEs (range, 0–19). Efficacy endpoints were included as PEs and SEs in 2 (5%) and 31 (78%) trials, respectively. Among the latter 31 trials that included 94 efficacy endpoints, 24, 22, 20, 9, and 8 reflected overall response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and disease control rate (DCR), respectively. ORR for BT was determined using various methods; however, the Response Evaluation Criteria in Solid Tumors (RECIST) was used less frequently in Group-A than in Group-B (p = 0.0039). Conclusions: Recent Phase I trials included efficacy endpoints as SEs, with ORR, PFS, or OS included in ~ 50% trials and DOR or DCR in ~ 25%. No established criteria exist for imaging evaluation of BTs. Phase I trials involving mixed solid tumor cohorts revealed challenges in designing methods to assess the exploratory efficacy of BTs. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. Mild cognitive impairment predicts the onset of Sarcopenia: a longitudinal analysis from the English Longitudinal Study on Ageing.
- Author
-
Ragusa, Francesco Saverio, Veronese, Nicola, Vernuccio, Laura, Dominguez, Ligia J, Smith, Lee, Bolzetta, Francesco, Koyanagi, Ai, Monastero, Roberto, and Barbagallo, Mario
- Abstract
Background: Mild cognitive impairment (MCI) and sarcopenia are two common conditions in older people. It is not widely known if MCI could predict the onset of sarcopenia. Therefore, we aimed to investigate whether MCI could predict the occurrence of sarcopenia in a population of older adults. Methods: In the ELSA (English Longitudinal Study on Ageing), MCI was defined as the absence of dementia, preserved functional capacity and low performance in three objective cognitive tests. Sarcopenia was diagnosed as having low handgrip strength and low skeletal muscle mass index during follow-up. The longitudinal association between MCI at the baseline and incident sarcopenia was assessed using a multivariable logistic regression model, reporting the data as adjusted odds ratios (OR) and 95% confidence intervals (95%CI). Results: 3,106 participants (mean age of 63.1 years; 55.3% males) were included. People with MCI reported significantly lower mean handgrip strength values and Skeletal Mass Index (SMI), as well as a higher prevalence of obesity at baseline. At baseline, 729 people had MCI and during the ten years follow-up period, 12.1% of the initial population included had sarcopenia. On multivariate analysis, adjusted for 18 potential confounders, the presence of MCI (OR = 1.236; 95%CI: 1.090–1.596, p = 0.01) significantly predicted the onset of sarcopenia during follow-up. Conclusion: The presence of MCI at baseline was associated with a higher incidence of sarcopenia at ten-years follow-up, demonstrating a likely role of MCI as a predictor of the onset of sarcopenia in older people. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Sex differences in the global burden of multidrugresistant tuberculosis without extensive drug resistance in the general population and people living with HIV/AIDS, 1990-2019.
- Author
-
CHOI, J., PARK, J., SON, Y., KIM, S., KWON, R., LEE, H., RAHMATI, M., KANG, J., WOO, H. G., KOYANAGI, A., SMITH, L., LÓPEZ SÁNCHEZ, G. F., DRAGIOTI, E., LEE, S.-H., CHO, W., KIM, H. J., SHIN, J. I., and YON, D. K.
- Abstract
OBJECTIVE: Currently, human immunodeficiency virus (HIV) and multi-drug resistant tuberculosis (MDR-TB) without extensive drug resistance (XDR) are significant challenges in terms of the global burden of disease. This study aimed to evaluate the trends of the global burden of MDR-TB without XDR and HIV/AIDS-MDR-TB without XDR, focusing on differences in socioeconomic status and sex for 204 countries and territories across periods from 1990 to 2019. MATERIALS AND METHODS: D ata from t he Global Burden of Disease (GBD) 2019 study were obtained to construct a separate index measuring the burden of MDR-TB without XDR and HIV/AIDS-MDR-TB without XDR. Incidence, preva-lence, mortality, and disability-adjusted life years (DALYs) were calculated for each case and group. A population-attributable fraction approach was used to assess mortality and incidence of HIV/AIDS and MDR-TB coinfection. 95% uncertainty intervals (UIs) were presented for all measures. RESULTS: Our global estimates suggest that there were approximately 450,000 (95% UI 247,000-785,000) incident cases of MDRTB without XDR and 109,000 (43,000-210,000) deaths caused by MDR-TB without XDR among individuals who were HIV-negative in 2019. For HIV-positive individuals, the corresponding figures were approximately 47,000 (33,000-67,000) incident cases of MDR-TB and 19,000 (8,000-36,000) deaths due to MDR-TB in the same year. In 2019, higher numbers of incident cases and deaths were observed in males compared to females among individuals who were HIV-negative. Conversely, for HIV-positive individuals, females had higher numbers of incident cases and deaths compared to males. Specifically, the estimated numbers for incident cases were 23,000 (15,000-33,000) for females and 24,000 (17,000-35,000) for males, while the estimated numbers for deaths were 9,600 (4,000-17,900) for females and 9,800 (4,100-18,500) for males. Male-to-female ratios have remained above 1.0 from 1990 to 2019 in both incident cases and number of deaths for HIV-negative individuals. However, for HIV and MDR-TB coinfection, both ratios were below 1.0 in most of the time series. CONCLUSIONS: Males had more cases and deaths due to MDR-TB without XDR than females in HIV-negative patients, while females faced a higher incidence and mortality in HIV/AIDS-MDR-TB without XDR. Interventions are needed to deal with such factors, which increase the burden of coinfection among females across the world. [ABSTRACT FROM AUTHOR]
- Published
- 2024
10. Association between sedentary behavior and dynapenic abdominal obesity among older adults from low- and middle-income countries.
- Author
-
Smith, Lee, López Sánchez, Guillermo F., Rahmati, Masoud, Tully, Mark A., Pizzol, Damiano, Veronese, Nicola, Soysal, Pinar, Kostev, Karel, Yon, Dong Keon, Butler, Laurie, Shin, Jae Il, and Koyanagi, Ai
- Abstract
Background: Sedentary behavior, or time spent sitting, may increase risk for dynapenic abdominal obesity (DAO), but there are currently no studies on this topic. Aims: Therefore, we investigated the association between sedentary behaviour and DAO in a nationally representative sample of older adults from six low- and middle-income countries. Methods: Cross-sectional data from the Study on Global AGEing and Adult Health were analysed. Dynapenia was defined as handgrip strength < 26 kg for men and < 16 kg for women. Abdominal obesity was defined as waist circumference of > 88 cm (> 80 cm for Asian countries) for women and > 102 cm (> 90 cm) for men. DAO was defined as having both dynapenia and abdominal obesity. Self-reported sedentary behavior was categorized as ≥ 8 h/day (high sedentary behaviour) or < 8 h/day. Multivariable multinomial logistic regression was conducted. Results: Data on 20,198 adults aged ≥ 60 years were analyzed [mean (SD) age 69.3 (13.1) years; 54.1% females]. In the overall sample, ≥ 8 h of sedentary behavior per day (vs. <8 h) was significantly associated with 1.52 (95%CI = 1.11–2.07) times higher odds for DAO (vs. no dynapenia and no abdominal obesity), and this was particularly pronounced among males (OR = 2.27; 95%CI = 1.42–3.62). Highly sedentary behavior was not significantly associated with dynapenia alone or abdominal obesity alone. Discussion: High sedentary behaviour may increase risk for DAO among older adults. Conclusions: Interventions to reduce sedentary behaviour may also lead to reduction of DAO and its adverse health outcomes, especially among males, pending future longitudinal research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Temporal Trends of Physical Fights and Physical Attacks Among Adolescents Aged 12–15 years From 30 Countries From Africa, Asia, and the Americas.
- Author
-
Smith, Lee, López Sánchez, Guillermo F., Oh, Hans, Jacob, Louis, Kostev, Karel, Rahmati, Masoud, Butler, Laurie, Keyes, Helen, Barnett, Yvonne, Yon, Dong Keon, Shin, Jae Il, and Koyanagi, Ai
- Abstract
There is a scarcity of literature on temporal trends in physical fighting and physical attacks among the global adolescent population. Therefore, we aimed to examine these trends in a nationally representative sample of school-going adolescents aged 12–15 years from 30 countries in Africa, Asia, and the Americas, for which temporal trends of physical fighting and physical attacks are largely unknown. Cross-sectional data from the Global School-based Student Health Survey 2003–2017 were analyzed. Self-reported data on past 12-month physical fights and physical attacks were collected. For each survey, the prevalence and 95% confidence interval of physical fights and physical attacks were calculated. Linear regression models were used to examine crude linear trends. Data on 190,493 students aged 12–15 years were analyzed [mean (standard deviation) age 13.7 (1.0) years; 48.9% boys]. The mean prevalence of past 12-month physical fight and physical attack was 36.5% and 37.2%, respectively. Significant decreasing trends in physical fights were observed in 16/30 countries, while significant increasing trends were found in 2/30 countries. For physical attacks, significant decreasing and increasing trends were observed in 13/26 and 1/26 countries, respectively. The remaining countries showed stable trends. It is encouraging that decreasing trends in physical fighting and physical attacks were observed across a large number of countries. However, stable trends were also common, while increasing trends also existed, suggesting that global efforts to address adolescent violence are still required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints
- Author
-
Watanabe, Shinya, Nonaka, Takahiro, Maeda, Makoto, Yamada, Masanobu, Sugii, Narushi, Hashimoto, Koichi, Takano, Shingo, Koyanagi, Tomoyoshi, Arakawa, Yoshihiro, and Ishikawa, Eiichi
- Abstract
Background: Appropriate exploratory efficacy data from Phase I trials are vital for subsequent phases. Owing to the uniqueness of brain tumors (BTs), use of different strategies to evaluate efficacy is warranted. We studied exploratory efficacy evaluation in Phase I trials involving BTs. Methods: Using Clarivate’s Cortellis
™ , 42 Phase I trials of BT interventions conducted from 2020 to 2022 were analyzed for efficacy endpoints, which were set as primary endpoints (PEs) or secondary endpoints (SEs). Additionally, these metrics were compared in two subgroups: trials including only BTs (Group-A) and those including BTs among mixed solid tumors (Group-B). Results: Selected studies included a median of 1.5 PEs (range, 1–6) and 5 SEs (range, 0–19). Efficacy endpoints were included as PEs and SEs in 2 (5%) and 31 (78%) trials, respectively. Among the latter 31 trials that included 94 efficacy endpoints, 24, 22, 20, 9, and 8 reflected overall response rate (ORR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and disease control rate (DCR), respectively. ORR for BT was determined using various methods; however, the Response Evaluation Criteria in Solid Tumors (RECIST) was used less frequently in Group-A than in Group-B (p= 0.0039). Conclusions: Recent Phase I trials included efficacy endpoints as SEs, with ORR, PFS, or OS included in ~ 50% trials and DOR or DCR in ~ 25%. No established criteria exist for imaging evaluation of BTs. Phase I trials involving mixed solid tumor cohorts revealed challenges in designing methods to assess the exploratory efficacy of BTs.- Published
- 2024
- Full Text
- View/download PDF
13. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Author
-
Schumacher, Austin E, Kyu, Hmwe Hmwe, Aali, Amirali, Abbafati, Cristiana, Abbas, Jaffar, Abbasgholizadeh, Rouzbeh, Abbasi, Madineh Akram, Abbasian, Mohammadreza, Abd ElHafeez, Samar, Abdelmasseh, Michael, Abd-Elsalam, Sherief, Abdelwahab, Ahmed, Abdollahi, Mohammad, Abdoun, Meriem, Abdullahi, Auwal, Abdurehman, Ame Mehadi, Abebe, Mesfin, Abedi, Aidin, Abedi, Armita, Abegaz, Tadesse M, Abeldaño Zuñiga, Roberto Ariel, Abhilash, E S, Abiodun, Olugbenga Olusola, Aboagye, Richard Gyan, Abolhassani, Hassan, Abouzid, Mohamed, Abreu, Lucas Guimarães, Abrha, Woldu Aberhe, Abrigo, Michael R M, Abtahi, Dariush, Abu Rumeileh, Samir, Abu-Rmeileh, Niveen ME, Aburuz, Salahdein, Abu-Zaid, Ahmed, Acuna, Juan Manuel, Adair, Tim, Addo, Isaac Yeboah, Adebayo, Oladimeji M, Adegboye, Oyelola A, Adekanmbi, Victor, Aden, Bashir, Adepoju, Abiola Victor, Adetunji, Charles Oluwaseun, Adeyeoluwa, Temitayo Esther, Adeyomoye, Olorunsola Israel, Adha, Rishan, Adibi, Amin, Adikusuma, Wirawan, Adnani, Qorinah Estiningtyas Sakilah, Adra, Saryia, Afework, Abel, Afolabi, Aanuoluwapo Adeyimika, Afraz, Ali, Afyouni, Shadi, Afzal, Saira, Agasthi, Pradyumna, Aghamiri, Shahin, Agodi, Antonella, Agyemang-Duah, Williams, Ahinkorah, Bright Opoku, Ahmad, Aqeel, Ahmad, Danish, Ahmad, Firdos, Ahmad, Muayyad M, Ahmad, Tauseef, Ahmadi, Keivan, Ahmadzade, Amir Mahmoud, Ahmadzade, Mohadese, Ahmed, Ayman, Ahmed, Haroon, Ahmed, Luai A, Ahmed, Muktar Beshir, Ahmed, Syed Anees, Ajami, Marjan, Aji, Budi, Ajumobi, Olufemi, Akalu, Gizachew Taddesse, Akara, Essona Matatom, Akinosoglou, Karolina, Akkala, Sreelatha, Akyirem, Samuel, Al Hamad, Hanadi, Al Hasan, Syed Mahfuz, Al Homsi, Ammar, Al Qadire, Mohammad, Ala, Moein, Aladelusi, Timothy Olukunle, AL-Ahdal, Tareq Mohammed Ali, Alalalmeh, Samer O, Al-Aly, Ziyad, Alam, Khurshid, Alam, Manjurul, Alam, Zufishan, Al-amer, Rasmieh Mustafa, Alanezi, Fahad Mashhour, Alanzi, Turki M, Albashtawy, Mohammed, AlBataineh, Mohammad T, Aldridge, Robert W, Alemi, Sharifullah, Al-Eyadhy, Ayman, Al-Gheethi, Adel Ali Saeed, Alhabib, Khalid F, Alhalaiqa, Fadwa Alhalaiqa Naji, Al-Hanawi, Mohammed Khaled, Ali, Abid, Ali, Akhtar, Ali, Beriwan Abdulqadir, Ali, Hassam, Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait Shujait, Ali, Zahid, Alian Samakkhah, Shohreh, Alicandro, Gianfranco, Alif, Sheikh Mohammad, Aligol, Mohammad, Alimi, Rasoul, Aliyi, Ahmednur Adem, Al-Jumaily, Adel, Aljunid, Syed Mohamed, Almahmeed, Wael, Al-Marwani, Sabah, Al-Maweri, Sadeq Ali Ali, Almazan, Joseph Uy, Al-Mekhlafi, Hesham M, Almidani, Omar, Alomari, Mahmoud A, Alonso, Nivaldo, Alqahtani, Jaber S, Alqutaibi, Ahmed Yaseen, Al-Sabah, Salman Khalifah, Altaf, Awais, Al-Tawfiq, Jaffar A, Altirkawi, Khalid A, Alvi, Farrukh Jawad, Alwafi, Hassan, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H, Amare, Azmeraw T, Ameyaw, Edward Kwabena, Amhare, Abebe Feyissa, Amin, Tarek Tawfik, Amindarolzarbi, Alireza, Aminian Dehkordi, Javad, Amiri, Sohrab, Amu, Hubert, Amugsi, Dickson A, Amzat, Jimoh, Ancuceanu, Robert, Anderlini, Deanna, Andrade, Pedro Prata, Andrei, Catalina Liliana, Andrei, Tudorel, Angappan, Dhanalakshmi, Anil, Abhishek, Anjum, Afifa, Antony, Catherine M, Antriyandarti, Ernoiz, Anuoluwa, Iyadunni Adesola, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward, Appiah, Seth Christopher Yaw, Aqeel, Muhammad, Arabloo, Jalal, Arabzadeh Bahri, Razman, Arab-Zozani, Morteza, Arafat, Mosab, Araújo, Ana Margarida, Aravkin, Aleksandr Y, Aremu, Abdulfatai, Ariffin, Hany, Aripov, Timur, Armocida, Benedetta, Arooj, Mahwish, Artamonov, Anton A, Artanti, Kurnia Dwi, Arulappan, Judie, Aruleba, Idowu Thomas, Aruleba, Raphael Taiwo, Arumugam, Ashokan, Asaad, Malke, Asgary, Saeed, Ashemo, Mubarek Yesse, Ashraf, Muhammad, Asika, Marvellous O, Athari, Seyyed Shamsadin, Atout, Maha Moh'd Wahbi, Atreya, Alok, Attia, Sameh, Aujayeb, Avinash, Avan, Abolfazl, Awotidebe, Adedapo Wasiu, Ayala Quintanilla, Beatriz Paulina, Ayanore, Martin Amogre, Ayele, Getnet Melaku, Ayuso-Mateos, Jose L, Ayyoubzadeh, Seyed Mohammad, Azadnajafabad, Sina, Azhar, Gulrez Shah, Aziz, Shahkaar, Azzam, Ahmed Y, Babashahi, Mina, Babu, Abraham Samuel, Badar, Muhammad, Badawi, Alaa, Badiye, Ashish D, Baghdadi, Soroush, Bagheri, Nasser, Bagherieh, Sara, Bah, Sulaiman, Bahadorikhalili, Saeed, Bai, Jianjun, Bai, Ruhai, Baker, Jennifer L, Bakkannavar, Shankar M, Bako, Abdulaziz T, Balakrishnan, Senthilkumar, Balogun, Saliu A, Baltatu, Ovidiu Constantin, Bam, Kiran, Banach, Maciej, Bandyopadhyay, Soham, Banik, Biswajit, Banik, Palash Chandra, Bansal, Hansi, Barati, Shirin, Barchitta, Martina, Bardhan, Mainak, Barker-Collo, Suzanne Lyn, Barone-Adesi, Francesco, Barqawi, Hiba Jawdat, Barr, Ronald D, Barrero, Lope H, Basharat, Zarrin, Bashir, Asma'u I J, Bashiru, Hameed Akande, Baskaran, Pritish, Basnyat, Buddha, Bassat, Quique, Basso, João Diogo, Basu, Saurav, Batra, Kavita, Batra, Ravi, Baune, Bernhard T, Bayati, Mohsen, Bayileyegn, Nebiyou Simegnew, Beaney, Thomas, Bedi, Neeraj, Begum, Tahmina, Behboudi, Emad, Behnoush, Amir Hossein, Beiranvand, Maryam, Bejarano Ramirez, Diana Fernanda, Belgaumi, Uzma Iqbal, Bell, Michelle L, Bello, Aminu K, Bello, Muhammad Bashir, Bello, Olorunjuwon Omolaja, Belo, Luis, Beloukas, Apostolos, Bendak, Salaheddine, Bennett, Derrick A, Bensenor, Isabela M, Benzian, Habib, Berezvai, Zombor, Berman, Adam E, Bermudez, Amiel Nazer C, Bettencourt, Paulo J G, Beyene, Habtamu B, Beyene, Kebede A, Bhagat, Devidas S, Bhagavathula, Akshaya Srikanth, Bhala, Neeraj, Bhalla, Ashish, Bhandari, Dinesh, Bhardwaj, Nikha, Bhardwaj, Pankaj, Bhardwaj, Prarthna V, Bhargava, Ashish, Bhaskar, Sonu, Bhat, Vivek, Bhatti, Gurjit Kaur, Bhatti, Jasvinder Singh, Bhatti, Manpreet S, Bhatti, Rajbir, Bhutta, Zulfiqar A, Bikbov, Boris, Binmadi, Nada, Bintoro, Bagas Suryo, Biondi, Antonio, Bisignano, Catherine, Bisulli, Francesca, Biswas, Atanu, Biswas, Raaj Kishore, Bitaraf, Saeid, Bjørge, Tone, Bleyer, Archie, Boampong, Mary Sefa, Bodolica, Virginia, Bodunrin, Aadam Olalekan, Bolarinwa, Obasanjo Afolabi, Bonakdar Hashemi, Milad, Bonny, Aime, Bora, Kaustubh, Bora Basara, Berrak, Borodo, Safiya Bala, Borschmann, Rohan, Botero Carvajal, Alejandro, Bouaoud, Souad, Boudalia, Sofiane, Boyko, Edward J, Bragazzi, Nicola Luigi, Braithwaite, Dejana, Brenner, Hermann, Britton, Gabrielle, Browne, Annie J, Brunoni, Andre R, Bulamu, Norma B, Bulto, Lemma N, Buonsenso, Danilo, Burkart, Katrin, Burns, Richard A, Burugina Nagaraja, Sharath, Busse, Reinhard, Bustanji, Yasser, Butt, Zahid A, Caetano dos Santos, Florentino Luciano, Cai, Tianji, Calina, Daniela, Cámera, Luis Alberto, Campos, Luciana Aparecida, Campos-Nonato, Ismael R, Cao, Chao, Cardenas, Carlos Alberto, Cárdenas, Rosario, Carr, Sinclair, Carreras, Giulia, Carrero, Juan J, Carugno, Andrea, Carvalho, Felix, Carvalho, Márcia, Castaldelli-Maia, Joao Mauricio, Castañeda-Orjuela, Carlos A, Castelpietra, Giulio, Catalá-López, Ferrán, Catapano, Alberico L, Cattaruzza, Maria Sofia, Caye, Arthur, Cederroth, Christopher R, Cembranel, Francieli, Cenderadewi, Muthia, Cercy, Kelly M, Cerin, Ester, Cevik, Muge, Chacón-Uscamaita, Pamela R Uscamaita, Chahine, Yaacoub, Chakraborty, Chiranjib, Chan, Jeffrey Shi Kai, Chang, Chin-Kuo, Charalampous, Periklis, Charan, Jaykaran, Chattu, Vijay Kumar, Chatzimavridou-Grigoriadou, Victoria, Chavula, Malizgani Paul, Cheema, Huzaifa Ahmad, Chen, An-Tian, Chen, Haowei, Chen, Lingxiao, Chen, Meng Xuan, Chen, Simiao, Cherbuin, Nicolas, Chew, Derek S, Chi, Gerald, Chirinos-Caceres, Jesus Lorenzo, Chitheer, Abdulaal, Cho, So Mi Jemma, Cho, William C S, Chong, Bryan, Chopra, Hitesh, Choudhary, Rahul, Chowdhury, Rajiv, Chu, Dinh-Toi, Chukwu, Isaac Sunday, Chung, Eric, Chung, Eunice, Chung, Sheng-Chia, Cini, Karly I, Clark, Cain C T, Coberly, Kaleb, Columbus, Alyssa, Comfort, Haley, Conde, Joao, Conti, Sara, Cortesi, Paolo Angelo, Costa, Vera Marisa, Cousin, Ewerton, Cowden, Richard G, Criqui, Michael H, Cruz-Martins, Natália, Culbreth, Garland T, Cullen, Patricia, Cunningham, Matthew, da Silva e Silva, Daniel, Dadana, Sriharsha, Dadras, Omid, Dai, Zhaoli, Dalal, Koustuv, Dalli, Lachlan L, Damiani, Giovanni, D'Amico, Emanuele, Daneshvar, Sara, Darwesh, Aso Mohammad, Das, Jai K, Das, Saswati, Dash, Nihar Ranjan, Dashti, Mohsen, Dávila-Cervantes, Claudio Alberto, Davis Weaver, Nicole, Davletov, Kairat, De Leo, Diego, Debele, Aklilu Tamire, Degenhardt, Louisa, Dehbandi, Reza, Deitesfeld, Lee, Delgado-Enciso, Ivan, Delgado-Ortiz, Laura, Demant, Daniel, Demessa, Berecha Hundessa, Demetriades, Andreas K, Deng, Xinlei, Denova-Gutiérrez, Edgar, Deribe, Kebede, Dervenis, Nikolaos, Des Jarlais, Don C, Desai, Hardik Dineshbhai, Desai, Rupak, Deuba, Keshab, Devanbu, Vinoth Gnana Chellaiyan, Dey, Sourav, Dhali, Arkadeep, Dhama, Kuldeep, Dhimal, Mandira Lamichhane, Dhimal, Meghnath, Dhingra, Sameer, Dias da Silva, Diana, Diaz, Daniel, Dima, Adriana, Ding, Delaney D, Dirac, M Ashworth, Dixit, Abhinav, Dixit, Shilpi Gupta, Do, Thanh Chi, Do, Thao Huynh Phuong, do Prado, Camila Bruneli, Dodangeh, Masoud, Dokova, Klara Georgieva, Dolecek, Christiane, Dorsey, E Ray, dos Santos, Wendel Mombaque, Doshi, Rajkumar, Doshmangir, Leila, Douiri, Abdel, Dowou, Robert Kokou, Driscoll, Tim Robert, Dsouza, Haneil Larson, Dube, John, Dumith, Samuel C, Dunachie, Susanna J, Duncan, Bruce B, Duraes, Andre Rodrigues, Duraisamy, Senbagam, Durojaiye, Oyewole Christopher, Dutta, Sulagna, Dzianach, Paulina Agnieszka, Dziedzic, Arkadiusz Marian, Ebenezer, Oluwakemi, Eboreime, Ejemai, Ebrahimi, Alireza, Echieh, Chidiebere Peter, Ed-Dra, Abdelaziz, Edinur, Hisham Atan, Edvardsson, David, Edvardsson, Kristina, Efendi, Defi, Efendi, Ferry, Eghdami, Shayan, Eikemo, Terje Andreas, Eini, Ebrahim, Ekholuenetale, Michael, Ekpor, Emmanuel, Ekundayo, Temitope Cyrus, El Arab, Rabie Adel, El Morsi, Doaa Abdel Wahab, El Sayed Zaki, Maysaa, El Tantawi, Maha, Elbarazi, Iffat, Elemam, Noha Mousaad, Elgar, Frank J, Elgendy, Islam Y, ElGohary, Ghada Metwally Tawfik, Elhabashy, Hala Rashad, Elhadi, Muhammed, Elmeligy, Omar Abdelsadek Abdou, Elshaer, Mohammed, Elsohaby, Ibrahim, Emami Zeydi, Amir, Emamverdi, Mehdi, Emeto, Theophilus I, Engelbert Bain, Luchuo, Erkhembayar, Ryenchindorj, Eshetie, Tesfahun C, Eskandarieh, Sharareh, Espinosa-Montero, Juan, Estep, Kara, Etaee, Farshid, Eze, Ugochukwu Anthony, Fabin, Natalia, Fadaka, Adewale Oluwaseun, Fagbamigbe, Adeniyi Francis, Fahimi, Saman, Falzone, Luca, Farinha, Carla Sofia e Sá, Faris, MoezAlIslam Ezzat Mahmoud, Farjoud Kouhanjani, Mohsen, Faro, Andre, Farrokhpour, Hossein, Fatehizadeh, Ali, Fattahi, Hamed, Fauk, Nelsensius Klau, Fazeli, Pooria, Feigin, Valery L, Fekadu, Ginenus, Fereshtehnejad, Seyed-Mohammad, Feroze, Abdullah Hamid, Ferrante, Daniela, Ferrara, Pietro, Ferreira, Nuno, Fetensa, Getahun, Filip, Irina, Fischer, Florian, Flavel, Joanne, Flaxman, Abraham D, Flor, Luisa S, Florin, Bobirca Teodor, Folayan, Morenike Oluwatoyin, Foley, Kristen Marie, Fomenkov, Artem Alekseevich, Force, Lisa M, Fornari, Carla, Foroutan, Behzad, Foschi, Matteo, Francis, Kate Louise, Franklin, Richard Charles, Freitas, Alberto, Friedman, Joseph, Friedman, Sara D, Fukumoto, Takeshi, Fuller, John E, Gaal, Peter Andras, Gadanya, Muktar A, Gaihre, Santosh, Gaipov, Abduzhappar, Gakidou, Emmanuela, Galali, Yaseen, Galehdar, Nasrin, Gallus, Silvano, Gan, Quan, Gandhi, Aravind P, Ganesan, Balasankar, Garg, Jalaj, Gau, Shuo-Yan, Gautam, Prem, Gautam, Rupesh K, Gazzelloni, Federica, Gebregergis, Miglas W, Gebrehiwot, Mesfin, Gebremariam, Tesfay Brhane, Gerema, Urge, Getachew, Motuma Erena, Getachew, Tamirat, Gething, Peter W, Ghafourifard, Mansour, Ghahramani, Sulmaz, Ghailan, Khalid Yaser, Ghajar, Alireza, Ghanbarnia, Mohammad Javad, Ghasemi, MohammadReza, Ghasemzadeh, Afsaneh, Ghassemi, Fariba, Ghazy, Ramy Mohamed, Ghimire, Sailaja, Gholamian, Asadollah, Gholamrezanezhad, Ali, Ghorbani Vajargah, Pooyan, Ghozali, Ghozali, Ghozy, Sherief, Ghuge, Arun Digambarrao, Gialluisi, Alessandro, Gibson, Ruth Margaret, Gil, Artyom Urievich, Gill, Paramjit Singh, Gill, Tiffany K, Gillum, Richard F, Ginindza, Themba G, Girmay, Alem, Glasbey, James C, Gnedovskaya, Elena V, Göbölös, Laszlo, Goel, Amit, Goldust, Mohamad, Golechha, Mahaveer, Goleij, Pouya, Golestanfar, Arefeh, Golinelli, Davide, Gona, Philimon N, Goudarzi, Houman, Goudarzian, Amir Hossein, Goyal, Anmol, Greenhalgh, Scott, Grivna, Michal, Guarducci, Giovanni, Gubari, Mohammed Ibrahim Mohialdeen, Gudeta, Mesay Dechasa, Guha, Avirup, Guicciardi, Stefano, Gunawardane, Damitha Asanga, Gunturu, Sasidhar, Guo, Cui, Gupta, Anish Kumar, Gupta, Bhawna, Gupta, Indarchand Ratanlal, Gupta, Rajat Das, Gupta, Sapna, Gupta, Veer Bala, Gupta, Vijai Kumar, Gupta, Vivek Kumar, Gutiérrez, Reyna Alma, Habibzadeh, Farrokh, Habibzadeh, Parham, Hachinski, Vladimir, Haddadi, Mohammad, Haddadi, Rasool, Haep, Nils, Hajj Ali, Adel, Halboub, Esam S, Halim, Sobia Ahsan, Hall, Brian J, Haller, Sebastian, Halwani, Rabih, Hamadeh, Randah R, Hamagharib Abdullah, Kanaan, Hamidi, Samer, Hamiduzzaman, Mohammad, Hammoud, Ahmad, Hanifi, Nasrin, Hankey, Graeme J, Hannan, Md Abdul, Haque, Md Nuruzzaman, Harapan, Harapan, Haro, Josep Maria, Hasaballah, Ahmed I, Hasan, Faizul, Hasan, Ikramul, Hasan, M Tasdik, Hasani, Hamidreza, Hasanian, Mohammad, Hasanpour- Dehkordi, Ali, Hassan, Abbas M, Hassan, Amr, Hassanian-Moghaddam, Hossein, Hassanipour, Soheil, Haubold, Johannes, Havmoeller, Rasmus J, Hay, Simon I, Hbid, Youssef, Hebert, Jeffrey J, Hegazi, Omar E, Heidari, Golnaz, Heidari, Mohammad, Heidari-Foroozan, Mahsa, Heidari-Soureshjani, Reza, Helfer, Bartosz, Herteliu, Claudiu, Hesami, Hamed, Hettiarachchi, Dineshani, Heyi, Demisu Zenbaba, Hezam, Kamal, Hiraike, Yuta, Hoffman, Howard J, Holla, Ramesh, Horita, Nobuyuki, Hossain, Md Belal, Hossain, Md Mahbub, Hossain, Sahadat, Hosseini, Mohammad-Salar, Hosseinzadeh, Hassan, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Hostiuc, Sorin, Hsairi, Mohamed, Hsieh, Vivian Chia-rong, Hu, Chengxi, Huang, Junjie, Huda, Md Nazmul, Hugo, Fernando N, Hultström, Michael, Hussain, Javid, Hussain, Salman, Hussein, Nawfal R, Huy, Le Duc, Huynh, Hong-Han, Hwang, Bing-Fang, Ibitoye, Segun Emmanuel, Idowu, Oluwatope Olaniyi, Ijo, Desta, Ikuta, Kevin S, Ilaghi, Mehran, Ilesanmi, Olayinka Stephen, Ilic, Irena M, Ilic, Milena D, Immurana, Mustapha, Inbaraj, Leeberk Raja, Iradukunda, Arnaud, Iravanpour, Farideh, Iregbu, Kenneth Chukwuemeka, Islam, Md Rabiul, Islam, Mohammad Mainul, Islam, Sheikh Mohammed Shariful, Islami, Farhad, Ismail, Nahlah Elkudssiah, Isola, Gaetano, Iwagami, Masao, Iwu, Chidozie C D, Iwu-Jaja, Chinwe Juliana, Iyer, Mahalaxmi, J, Linda Merin, Jaafari, Jalil, Jacob, Louis, Jacobsen, Kathryn H, Jadidi-Niaragh, Farhad, Jafarinia, Morteza, Jaggi, Khushleen, Jahankhani, Kasra, Jahanmehr, Nader, Jahrami, Haitham, Jain, Akhil, Jain, Nityanand, Jairoun, Ammar Abdulrahman, Jakovljevic, Mihajlo, Jalilzadeh Yengejeh, Reza, Jamshidi, Elham, Jani, Chinmay T, Janko, Mark M, Jatau, Abubakar Ibrahim, Jayapal, Sathish Kumar, Jayaram, Shubha, Jeganathan, Jayakumar, Jema, Alelign Tasew, Jemere, Digisie Mequanint, Jeong, Wonjeong, Jha, Anil K, Jha, Ravi Prakash, Ji, John S, Jiang, Heng, Jin, Yingzhao, Jin, Yinzi, Johnson, Olatunji, Jomehzadeh, Nabi, Jones, Darwin Phan, Joo, Tamas, Joseph, Abel, Joseph, Nitin, Joshua, Charity Ehimwenma, Jozwiak, Jacek Jerzy, Jürisson, Mikk, Kaambwa, Billingsley, Kabir, Ali, Kabir, Hannaneh, Kabir, Zubair, Kadashetti, Vidya, Kahe, Farima, Kakodkar, Pradnya Vishal, Kalani, Rizwan, Kalankesh, Leila R, Kaliyadan, Feroze, Kalra, Sanjay, Kamath, Ashwin, Kamireddy, Arun, Kanagasabai, Thanigaivelan, Kandel, Himal, Kanmiki, Edmund Wedam, Kanmodi, Kehinde Kazeem, Kantar, Rami S, Kapoor, Neeti, Karajizadeh, Mehrdad, Karami Matin, Behzad, Karanth, Shama D, Karaye, Ibraheem M, Karim, Asima, Karimi, Hanie, Karimi, Salah Eddin, Karimi Behnagh, Arman, Karkhah, Samad, Karna, Ajit K, Kashoo, Faizan Zaffar, Kasraei, Hengameh, Kassaw, Nigussie Assefa, Kassebaum, Nicholas J, Kassel, Molly B, Katamreddy, Adarsh, Katikireddi, Srinivasa Vittal, Katoto, Patrick DMC, Kauppila, Joonas H, Kaur, Navjot, Kaydi, Neda, Kayibanda, Jeanne Françoise, Kayode, Gbenga A, Kazemi, Foad, Kazemian, Sina, Kazeminia, sara, Keikavoosi-Arani, Leila, Keller, Cathleen, Kempen, John H, Kerr, Jessica A, Kesse-Guyot, Emmanuelle, Keykhaei, Mohammad, Khadembashiri, Mohamad Mehdi, Khadembashiri, Mohammad Amin, Khafaie, Morteza Abdullatif, Khajuria, Himanshu, Khalafi, Mohammad, Khalaji, Amirmohammad, Khalid, Nauman, Khalil, Ibrahim A, Khamesipour, Faham, Khan, Asaduzzaman, Khan, Gulfaraz, Khan, Ikramullah, Khan, Imteyaz A, Khan, Maseer, Khan, Moien AB, Khan, Taimoor, Khan suheb, Mahammed Ziauddin, Khanmohammadi, Shaghayegh, Khatab, Khaled, Khatami, Fatemeh, Khavandegar, Armin, Khayat Kashani, Hamid Reza, Kheirallah, Khalid A, Khidri, Feriha Fatima, Khodadoust, Elaheh, Khormali, Moein, Khosrowjerdi, Mahmood, Khubchandani, Jagdish, Khusun, Helda, Kifle, Zemene Demelash, Kim, Grace, Kim, Jihee, Kimokoti, Ruth W, Kinzel, Kasey E, Kiross, Girmay Tsegay, Kisa, Adnan, Kisa, Sezer, Kiss, Juniper Boroka, Kivimäki, Mika, Klu, Desmond, Knudsen, Ann Kristin Skrindo, Kolahi, Ali-Asghar, Kompani, Farzad, Koren, Gerbrand, Kosen, Soewarta, Kostev, Karel, Kotnis, Ashwin Laxmikant, Koul, Parvaiz A, Koulmane Laxminarayana, Sindhura Lakshmi, Koyanagi, Ai, Kravchenko, Michael A, Krishan, Kewal, Krishna, Hare, Krishnamoorthy, Vijay, Krishnamoorthy, Yuvaraj, Krohn, Kris J, Kuate Defo, Barthelemy, Kubeisy, Connor M, Kucuk Bicer, Burcu, Kuddus, Md Abdul, Kuddus, Mohammed, Kuitunen, Ilari, Kujan, Omar, Kulimbet, Mukhtar, Kulkarni, Vishnutheertha, Kumar, Ashish, Kumar, Harish, Kumar, Nithin, Kumar, Rahul, Kumar, Shiv, Kumari, Madhulata, Kurmanova, Almagul, Kurmi, Om P, Kusnali, Asep, Kusuma, Dian, Kutluk, Tezer, Kuttikkattu, Ambily, Kyei, Evans F, Kyriopoulos, Ilias, La Vecchia, Carlo, Ladan, Muhammad Awwal, Laflamme, Lucie, Lahariya, Chandrakant, Lahmar, Abdelilah, Lai, Daphne Teck Ching, Laksono, Tri, Lal, Dharmesh Kumar, Lalloo, Ratilal, Lallukka, Tea, Lám, Judit, Lamnisos, Demetris, Lan, Tuo, Lanfranchi, Francesco, Langguth, Berthold, Lansingh, Van Charles, Laplante-Lévesque, Ariane, Larijani, Bagher, Larsson, Anders O, Lasrado, Savita, Latief, Kamaluddin, Latif, Mahrukh, Latifinaibin, Kaveh, Lauriola, Paolo, Le, Long Khanh Dao, Le, Nhi Huu Hanh, Le, Thao Thi Thu, Le, Trang Diep Thanh, Lee, Munjae, Lee, Paul H, Lee, Sang-woong, Lee, Seung Won, Lee, Wei-Chen, Lee, Yo Han, Legesse, Samson Mideksa, Leigh, James, Lenzi, Jacopo, Leong, Elvynna, Lerango, Temesgen L, Li, Ming-Chieh, Li, Wei, Li, Xiaopan, Li, Yichong, Li, Zhihui, Libra, Massimo, Ligade, Virendra S, Likaka, Andrew Tiyamike Makhiringa, Lim, Lee-Ling, Lin, Ro-Ting, Lin, Shuzhi, Lioutas, Vasileios-Arsenios, Listl, Stefan, Liu, Jue, Liu, Simin, Liu, Xiaofeng, Livingstone, Katherine M, Llanaj, Erand, Lo, Chun-Han, Loreche, Arianna Maever, Lorenzovici, László, Lotfi, Mojgan, Lotfizadeh, Masoud, Lozano, Rafael, Lubinda, Jailos, Lucchetti, Giancarlo, Lugo, Alessandra, Lunevicius, Raimundas, Ma, Jianing, Ma, Stefan, Ma, Zheng Feei, Mabrok, Mahmoud, Machairas, Nikolaos, Machoy, Monika, Madsen, Christian, Magaña Gómez, Javier A, Maghazachi, Azzam A, Maharaj, Sandeep B, Maharjan, Preeti, Mahjoub, Soleiman, Mahmoud, Mansour Adam, Mahmoudi, Elham, Mahmoudi, Morteza, Makram, Omar Mohamed, Malagón-Rojas, Jeadran N, Malakan Rad, Elaheh, Malekzadeh, Reza, Malhotra, Armaan K, Malhotra, Kashish, Malik, Ahmad Azam, Malik, Iram, Malinga, Lesibana Anthony, Malta, Deborah Carvalho, Mamun, Abdullah A, Manla, Yosef, Mannan, Fahmida, Mansoori, Yasaman, Mansour, Ali, Mansouri, Vahid, Mansournia, Mohammad Ali, Mantovani, Lorenzo Giovanni, Marasini, Bishnu P, Marateb, Hamid Reza, Maravilla, Joemer C, Marconi, Agustina M, Mardi, Parham, Marino, Mirko, Marjani, Abdoljalal, Marrugo Arnedo, Carlos Alberto, Martinez-Guerra, Bernardo Alfonso, Martinez-Piedra, Ramon, Martins, Cleodice A, Martins-Melo, Francisco Rogerlândio, Martorell, Miquel, Marx, Wolfgang, Maryam, Sharmeen, Marzo, Roy Rillera, Mate, Kedar K V, Matei, Clara N, Mathioudakis, Alexander G, Maude, Richard James, Maugeri, Andrea, May, Erin A, Mayeli, Mahsa, Mazaheri, Maryam, Mazidi, Mohsen, Mazzotti, Antonio, McAlinden, Colm, McGrath, John J, McKee, Martin, McKowen, Anna Laura W, McLaughlin, Susan A, McPhail, Michael A, McPhail, Steven M, Mechili, Enkeleint A, Mediratta, Rishi P, Meena, Jitendra Kumar, Mehari, Medhin, Mehlman, Max L, Mehra, Rahul, Mehrabani-Zeinabad, Kamran, Mehrabi Nasab, Entezar, Mehrotra, Ravi, Mekonnen, Mathewos M, Mendoza, Walter, Menezes, Ritesh G, Mengesha, Endalkachew Worku, Mensah, George A, Mensah, Laverne G, Mentis, Alexios-Fotios A, Meo, Sultan Ayoub, Meretoja, Atte, Meretoja, Tuomo J, Mersha, Abera M, Mesfin, Bezawit Afework, Mestrovic, Tomislav, Mhlanga, Adquate, Mhlanga, Laurette, Mi, Tianyue, Micha, Georgia, Michalek, Irmina Maria, Miller, Ted R, Mindlin, Sergey Nikolaevich, Minelli, Giada, Minh, Le Huu Nhat, Mini, GK, Minja, Neema W, Mirdamadi, Niloofar, Mirghafourvand, Mojgan, Mirica, Andreea, Mirinezhad, Seyed Kazem, Mirmosayyeb, Omid, Mirutse, Mizan Kiros, Mirza-Aghazadeh-Attari, Mohammad, Mirzaei, Maryam, Misgana, Tadesse, Misra, Sanjeev, Mitchell, Philip B, Mithra, Prasanna, Mittal, Chaitanya, Mittal, Madhukar, Moazen, Babak, Mohamed, Ahmed Ismail, Mohamed, Jama, Mohamed, Mouhand F H, Mohamed, Nouh Saad, Mohammad-Alizadeh-Charandabi, Sakineh, Mohammadi, Soheil, Mohammadian-Hafshejani, Abdollah, Mohammad-pour, Saeed, Mohammadshahi, Marita, Mohammed, Mustapha, Mohammed, Salahuddin, Mohammed, Shafiu, Mojiri-forushani, Hoda, Mokdad, Ali H, Mokhtarzadehazar, Peyman, Momenzadeh, Kaveh, Momtazmanesh, Sara, Monasta, Lorenzo, Moni, Mohammad Ali, Montazeri, Fateme, Moodi Ghalibaf, AmirAli, Moradi, Maryam, Moradi, Yousef, Moradi-Lakeh, Maziar, Moradinazar, Mehdi, Moradpour, Farhad, Moraga, Paula, Morawska, Lidia, Moreira, Rafael Silveira, Morovatdar, Negar, Morrison, Shane Douglas, Morze, Jakub, Mosaddeghi Heris, Reza, Mosser, Jonathan F, Mossialos, Elias, Mostafavi, Hakimeh, Mostofinejad, Amirmahdi, Mougin, Vincent, Mouodi, Simin, Mousavi, Parsa, Mousavi, Seyed Ehsan, Mousavi Khaneghah, Amin, Mpundu-Kaambwa, Christine, Mrejen, Matías, Mubarik, Sumaira, Muccioli, Lorenzo, Mueller, Ulrich Otto, Mughal, Faraz, Mukherjee, Sumoni, Mukoro, George Duke, Mulita, Admir, Mulita, Francesk, Muniyandi, Malaisamy, Munjal, Kavita, Musaigwa, Fungai, Musallam, Khaled M, Mustafa, Ghulam, Muthu, Sathish, Muthupandian, Saravanan, Myung, Woojae, Nabhan, Ashraf F, Nafukho, Fredrick Muyia, Nagarajan, Ahamarshan Jayaraman, Naghavi, Mohsen, Naghavi, Pirouz, Naik, Ganesh R, Naik, Gurudatta, Naimzada, Mukhammad David, Nair, Sanjeev, Nair, Tapas Sadasivan, Najmuldeen, Hastyar Hama Rashid, Naldi, Luigi, Nangia, Vinay, Nargus, Shumaila, Nascimento, Bruno Ramos, Nascimento, Gustavo G, Naser, Abdallah Y, Nasiri, Mohammad Javad, Natto, Zuhair S, Nauman, Javaid, Naveed, Muhammad, Nayak, Biswa Prakash, Nayak, Vinod C, Nayyar, Ashish Kumar, Nazri-Panjaki, Athare, Negash, Hadush, Negero, Amayu Kumesa, Negoi, Ionut, Negoi, Ruxandra Irina, Negru, Serban Mircea, Nejadghaderi, Seyed Aria, Nejjari, Chakib, Nematollahi, Mohammad Hadi, Nena, Evangelia, Nepal, Samata, Nesbit, Olivia D, Newton, Charles Richard James, Ngunjiri, Josephine W, Nguyen, Dang H, Nguyen, Phat Tuan, Nguyen, Phuong The, Nguyen, Tuan Thanh, Nguyen, Van Thanh, Nigatu, Yeshambel T, Nikolouzakis, Taxiarchis Konstantinos, Nikoobar, Ali, Nikpoor, Amin Reza, Nizam, Muhammad A, Nomura, Shuhei, Noreen, Mamoona, Noroozi, Nafise, Norouzian Baghani, Abbas, Norrving, Bo, Noubiap, Jean Jacques, Novotney, Amanda, Nri-Ezedi, Chisom Adaobi, Ntaios, George, Ntsekhe, Mpiko, Nuñez-Samudio, Virginia, Nurrika, Dieta, Oancea, Bogdan, Obamiro, Kehinde O, Odetokun, Ismail A, Ofakunrin, Akinyemi O D, Ogunsakin, Ropo Ebenezer, Oguta, James Odhiambo, Oh, In-Hwan, Okati-Aliabad, Hassan, Okeke, Sylvester Reuben, Okekunle, Akinkunmi Paul, Okidi, Lawrence, Okonji, Osaretin Christabel, Okwute, Patrick Godwin, Olagunju, Andrew T, Olaiya, Muideen Tunbosun, Olanipekun, Titilope O, Olatubi, Matthew Idowu, Olivas-Martinez, Antonio, Oliveira, Gláucia Maria Moraes, Oliver, Susan, Olorukooba, Abdulhakeem Abayomi, Olufadewa, Isaac Iyinoluwa, Olusanya, Bolajoko Olubukunola, Olusanya, Jacob Olusegun, Oluwafemi, Yinka Doris, Oluwatunase, Gideon Olamilekan, Omar, Hany A, Omer, Goran Latif, Ong, Sokking, Onwujekwe, Obinna E, Onyedibe, Kenneth Ikenna, Opio, John Nelson, Ordak, Michal, Orellana, E Roberto, Orisakwe, Orish Ebere, Orish, Verner N, Orru, Hans, Ortega-Altamirano, Doris V, Ortiz, Alberto, Ortiz-Brizuela, Edgar, Ortiz-Prado, Esteban, Osuagwu, Uchechukwu Levi, Otoiu, Adrian, Otstavnov, Nikita, Ouyahia, Amel, Ouyang, Guoqing, Owolabi, Mayowa O, Oyeyemi, Ifeoluwa Temitayo, Oyeyemi, Oyetunde T, Ozten, Yaz, P A, Mahesh Padukudru, Padubidri, Jagadish Rao, Pahlavikhah Varnosfaderani, Mahsa, Pal, Pramod Kumar, Palicz, Tamás, Palladino, Claudia, Palladino, Raffaele, Palma-Alvarez, Raul Felipe, Pana, Adrian, Panahi, Parsa, Pandey, Ashok, Pandi-Perumal, Seithikurippu R, Pando-Robles, Victoria, Pangaribuan, Helena Ullyartha, Panos, Georgios D, Pantazopoulos, Ioannis, Papadopoulou, Paraskevi, Pardhan, Shahina, Parikh, Romil R, Park, Seoyeon, Parthasarathi, Ashwaghosha, Pashaei, Ava, Pasupula, Deepak Kumar, Patel, Jenil R, Patel, Sangram Kishor, Pathan, Aslam Ramjan, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Patthipati, Venkata Suresh, Paudel, Uttam, Pawar, Shrikant, Pazoki Toroudi, Hamidreza, Pease, Spencer A, Peden, Amy E, Pedersini, Paolo, Peng, Minjin, Pensato, Umberto, Pepito, Veincent Christian Filipino, Peprah, Emmanuel K, Pereira, Gavin, Pereira, Jeevan, Pereira, Marcos, Peres, Mario F P, Perianayagam, Arokiasamy, Perico, Norberto, Petcu, Ionela-Roxana, Petermann-Rocha, Fanny Emily, Pezzani, Raffaele, Pham, Hoang Tran, Phillips, Michael R, Pierannunzio, Daniela, Pigeolet, Manon, Pigott, David M, Pilgrim, Thomas, Pinheiro, Marina, Piradov, Michael A, Plakkal, Nishad, Plotnikov, Evgenii, Poddighe, Dimitri, Pollner, Peter, Poluru, Ramesh, Pond, Constance Dimity, Postma, Maarten J, Poudel, Govinda Raj, Poudel, Lisasha, Pourali, Ghazaleh, Pourtaheri, Naeimeh, Prada, Sergio I, Pradhan, Pranil Man Singh, Prajapati, Vijay Kumar, Prakash, V, Prasad, Chandra P, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Purnobasuki, Hery, Purohit, Bharathi M, Puvvula, Jagadeesh, Qaisar, Rizwan, Qasim, Nameer Hashim, Qattea, Ibrahim, Qian, Gangzhen, Quan, Nguyen Khoi, Radfar, Amir, Radhakrishnan, Venkatraman, Raee, Pourya, Raeisi Shahraki, Hadi, Rafiei Alavi, Seyedeh Niloufar, Rafique, Ibrar, Raggi, Alberto, Rahim, Fakher, Rahman, Md Mosfequr, Rahman, Mosiur, Rahman, Muhammad Aziz, Rahman, Tafhimur, Rahmani, Amir Masoud, Rahmani, Shayan, Rahnavard, Niloufar, Rai, Pramila, Rajaa, Sathish, Rajabpour-Sanati, Ali, Rajput, Prashant, Ram, Prasanna, Ramadan, Hazem, Ramasamy, Shakthi Kumaran, Ramazanu, Sheena, Rana, Juwel, Rana, Kritika, Ranabhat, Chhabi Lal, Rancic, Nemanja, Rani, Smitha, Ranjan, Shubham, Rao, Chythra R, Rao, Indu Ramachandra, Rao, Mithun, Rao, Sowmya J, Rasali, Drona Prakash, Rasella, Davide, Rashedi, Sina, Rashedi, Vahid, Rashid, Ahmed Mustafa, Rasouli-Saravani, Ashkan, Rastogi, Prateek, Rasul, Azad, Ravangard, Ramin, Ravikumar, Nakul, Rawaf, David Laith, Rawaf, Salman, Rawassizadeh, Reza, Razeghian-Jahromi, Iman, Reddy, Murali Mohan Rama Krishna, Redwan, Elrashdy Moustafa Mohamed, Rehman, Faizan Ur, Reiner Jr, Robert C, Remuzzi, Giuseppe, Reshmi, Bhageerathy, Resnikoff, Serge, Reyes, Luis Felipe, Rezaee, Malihe, Rezaei, Negar, Rezaei, Nima, Rezaeian, Mohsen, Riaz, Mavra A, Ribeiro, Ana Isabel, Ribeiro, Daniel Cury, Rickard, Jennifer, Rios-Blancas, Maria Jesus, Robinson-Oden, Hannah Elizabeth, Rodrigues, Mónica, Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Rohilla, Ravi, Rohloff, Peter, Romadlon, Debby Syahru, Ronfani, Luca, Roshandel, Gholamreza, Roshanzamir, Sharareh, Rostamian, Morteza, Roy, Bedanta, Roy, Priyanka, Rubagotti, Enrico, Rumisha, Susan Fred, Rwegerera, Godfrey M, Rynkiewicz, Andrzej, S, Manjula, S N, Chandan, S Sunnerhagen, Katharina, Saad, Aly M A, Sabbatucci, Michela, Saber, Korosh, Saber-Ayad, Maha Mohamed, Sacco, Simona, Saddik, Basema, Saddler, Adam, Sadee, Bashdar Abuzed, Sadeghi, Ehsan, Sadeghi, Masoumeh, Sadeghian, Saeid, Saeed, Umar, Saeedi, Maryam, Safi, Sare, Sagar, Rajesh, Saghazadeh, Amene, Saheb Sharif-Askari, Narjes, Sahoo, Soumya Swaroop, Sahraian, Mohammad Ali, Sajedi, Seyed Aidin, Sajid, Mirza Rizwan, Sakshaug, Joseph W, Salahi, Saina, Salahi, Sarvenaz, Salamati, Payman, Salami, Afeez Abolarinwa, Salaroli, Luciane B, Saleh, Mohamed A, Salehi, Sana, Salem, Marwa Rashad, Salem, Mohammed Z Y, Salimi, Sohrab, Samadi Kafil, Hossein, Samadzadeh, Sara, Samara, Kamel A, Samargandy, Saad, Samodra, Yoseph Leonardo, Samuel, Vijaya Paul, Samy, Abdallah M, Sanabria, Juan, Sanadgol, Nima, Sanganyado, Edmond, Sanjeev, Rama Krishna, Sanmarchi, Francesco, Sanna, Francesca, Santri, Ichtiarini Nurullita, Santric-Milicevic, Milena M, Sarasmita, Made Ary, Saravanan, Aswini, Saravi, Babak, Sarikhani, Yaser, Sarkar, Chinmoy, Sarmiento-Suárez, Rodrigo, Sarode, Gargi Sachin, Sarode, Sachin C, Sarveazad, Arash, Sathian, Brijesh, Sathish, Thirunavukkarasu, Sattin, Davide, Saulam, Jennifer, Sawyer, Susan M, Saxena, Sonia, Saya, Ganesh Kumar, Sayadi, Yaser, Sayeed, Abu, Sayeed, Md Abu, Saylan, Mete, Scarmeas, Nikolaos, Schaarschmidt, Benedikt Michael, Schlee, Winfried, Schmidt, Maria Inês, Schuermans, Art, Schwebel, David C, Schwendicke, Falk, Šekerija, Mario, Selvaraj, Siddharthan, Semreen, Mohammad H, Senapati, Sabyasachi, Sengupta, Pallav, Senthilkumaran, Subramanian, Sepanlou, Sadaf G, Serban, Dragos, Sertsu, Addisu, Sethi, Yashendra, SeyedAlinaghi, SeyedAhmad, Seyedi, Seyed Arsalan, Shafaat, Amir, Shafaat, Omid, Shafie, Mahan, Shafiee, Arman, Shah, Nilay S, Shah, Pritik A, Shahabi, Saeed, Shahbandi, Ataollah, Shahid, Izza, Shahid, Samiah, Shahid, Wajeehah, Shahwan, Moyad Jamal, Shaikh, Masood Ali, Shakeri, Alireza, Shakil, Husain, Sham, Sunder, Shamim, Muhammad Aaqib, Shams-Beyranvand, Mehran, Shamshad, Hina, Shamshirgaran, Mohammad Ali, Shamsi, Mohammad Anas, Shanawaz, Mohd, Shankar, Abhishek, Sharfaei, Sadaf, Sharifan, Amin, Shariff, Mariam, Sharifi-Rad, Javad, Sharma, Manoj, Sharma, Rajesh, Sharma, Saurab, Sharma, Vishal, Shastry, Rajesh P, Shavandi, Amin, Shaw, David H, Shayan, Amir Mehdi, Shehabeldine, Amr Mohamed Elsayed, Sheikh, Aziz, Sheikhi, Rahim Ali, Shen, Jiabin, Shenoy, Manjunath Mala, Shetty, B Suresh Kumar, Shetty, Ranjitha S, Shey, Robert Adamu, Shiani, Amir, Shibuya, Kenji, Shiferaw, Desalegn, Shigematsu, Mika, Shin, Jae Il, Shin, Min-Jeong, Shiri, Rahman, Shirkoohi, Reza, Shittu, Aminu, Shiue, Ivy, Shivakumar, K M, Shivarov, Velizar, Shool, Sina, Shrestha, Sunil, Shuja, Kanwar Hamza, Shuval, Kerem, Si, Yafei, Sibhat, Migbar Mekonnen, Siddig, Emmanuel Edwar, Sigfusdottir, Inga Dora, Silva, João Pedro, Silva, Luís Manuel Lopes Rodrigues, Silva, Soraia, Simões, Jorge Piano, Simpson, Colin R, Singal, Anjali, Singh, Abhinav, Singh, Aditya, Singh, Ambrish, Singh, Balbir Bagicha, Singh, Baljinder, Singh, Mahendra, Singh, Mayank, Singh, Narinder Pal, Singh, Paramdeep, Singh, Surjit, Siraj, Md Shahjahan, Sitas, Freddy, Sivakumar, Shravan, Skryabin, Valentin Yurievich, Skryabina, Anna Aleksandrovna, Sleet, David A, Slepak, Erica Leigh N, Sohrabi, Hanye, Soleimani, Hamidreza, Soliman, Sameh S M, Solmi, Marco, Solomon, Yonatan, Song, Yimeng, Sorensen, Reed J D, Soriano, Joan B, Soyiri, Ireneous N, Spartalis, Michael, Sreeramareddy, Chandrashekhar T, Starnes, Joseph R, Starodubov, Vladimir I, Starodubova, Antonina V, Stefan, Simona Cătălina, Stein, Dan J, Steinbeis, Fridolin, Steiropoulos, Paschalis, Stockfelt, Leo, Stokes, Mark A, Stortecky, Stefan, Stranges, Saverio, Stroumpoulis, Konstantinos, Suleman, Muhammad, Suliankatchi Abdulkader, Rizwan, Sultana, Abida, Sun, Jing, Sunkersing, David, Susanty, Sri, Swain, Chandan Kumar, Sykes, Bryan L, Szarpak, Lukasz, Szeto, Mindy D, Szócska, Miklós, Tabaee Damavandi, Payam, Tabatabaei Malazy, Ozra, Tabatabaeizadeh, Seyed-Amir, Tabatabai, Shima, Tabb, Karen M, Tabish, Mohammad, Taborda-Barata, Luis M, Tabuchi, Takahiro, Tadesse, Birkneh Tilahun, Taheri, Amirmasoud, Taheri Abkenar, Yasaman, Taheri Soodejani, Moslem, Taherkhani, Amir, Taiba, Jabeen, Tajbakhsh, Ardeshir, Talaat, Iman M, Talukder, Ashis, Tamuzi, Jacques Lukenze, Tan, Ker-Kan, Tang, Haosu, Tang, Hong K, Tat, Nathan Y, Tat, Vivian Y, Tavakoli Oliaee, Razieh, Tavangar, Seyed Mohammad, Taveira, Nuno, Tebeje, Tsion Mulat, Tefera, Yibekal Manaye, Teimoori, Mojtaba, Temsah, Mohamad-Hani, Temsah, Reem Mohamad Hani, Teramoto, Masayuki, Tesfaye, Solomon Hailemariam, Thangaraju, Pugazhenthan, Thankappan, Kavumpurathu Raman, Thapa, Rajshree, Thapar, Rekha, Thomas, Nihal, Thrift, Amanda G, Thum, Chern Choong Chern, Tian, Jing, Tichopad, Ales, Ticoalu, Jansje Henny Vera, Tiruye, Tenaw Yimer, Tohidast, Seyed Abolfazl, Tonelli, Marcello, Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tram, Khai Hoan, Tran, Nghia Minh, Trico, Domenico, Trihandini, Indang, Tromans, Samuel Joseph, Truong, Vien T, Truyen, Thien Tan Tri Tai, Tsermpini, Evangelia Eirini, Tumurkhuu, Munkhtuya, Tung, Kang, Tyrovolas, Stefanos, Ubah, Chukwudi S, Udoakang, Aniefiok John, Udoh, Arit, Ulhaq, Inam, Ullah, Saeed, Ullah, Sana, Umair, Muhammad, Umar, Tungki Pratama, Umeokonkwo, Chukwuma David, Umesh, Anushri, Unim, Brigid, Unnikrishnan, Bhaskaran, Upadhyay, Era, Urso, Daniele, Vacante, Marco, Vahdani, Amir Mohammad, Vaithinathan, Asokan Govindaraj, Valadan Tahbaz, Sahel, Valizadeh, Rohollah, Van den Eynde, Jef, Varavikova, Elena, Varga, Orsolya, Varma, Siddhartha Alluri, Vart, Priya, Varthya, Shoban Babu, Vasankari, Tommi Juhani, Veerman, Lennert J, Venketasubramanian, Narayanaswamy, Venugopal, Deneshkumar, Verghese, Nicholas Alexander, Verma, Madhur, Verma, Pratibha, Veroux, Massimiliano, Verras, Georgios-Ioannis, Vervoort, Dominique, Vieira, Rafael José, Villafañe, Jorge Hugo, Villani, Leonardo, Villanueva, Gabriela Ines, Villeneuve, Paul J, Violante, Francesco S, Visontay, Rachel, Vlassov, Vasily, Vo, Bay, Vollset, Stein Emil, Volovat, Simona Ruxandra, Volovici, Victor, Vongpradith, Avina, Vos, Theo, Vujcic, Isidora S, Vukovic, Rade, Wado, Yohannes Dibaba, Wafa, Hatem A, Waheed, Yasir, Wamai, Richard G, Wang, Cong, Wang, Denny, Wang, Fang, Wang, Shu, Wang, Song, Wang, Yanzhong, Wang, Yuan-Pang, Ward, Paul, Watson, Stefanie, Weaver, Marcia R, Weerakoon, Kosala Gayan, Weiss, Daniel J, Weldemariam, Abrha Hailay, Wells, Katherine M, Wen, Yi Feng, Werdecker, Andrea, Westerman, Ronny, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Wijeratne, Tissa, Wilson, Shadrach, Wojewodzic, Marcin W, Wool, Eve E, Woolf, Anthony D, Wu, Dongze, Wulandari, Ratna Dwi, Xiao, Hong, Xu, Bin, Xu, Xiaoyue, Yadav, Lalit, Yaghoubi, Sajad, Yang, Lin, Yano, Yuichiro, Yao, Yao, Ye, Pengpeng, Yesera, Gesila Endashaw, Yesodharan, Renjulal, Yesuf, Subah Abderehim, Yiğit, Arzu, Yiğit, Vahit, Yip, Paul, Yon, Dong Keon, Yonemoto, Naohiro, You, Yuyi, Younis, Mustafa Z, Yu, Chuanhua, Zadey, Siddhesh, Zadnik, Vesna, Zafari, Nima, Zahedi, Mohammad, Zahid, Muhammad Nauman, Zahir, Mazyar, Zakham, Fathiah, Zaki, Nazar, Zakzuk, Josefina, Zamagni, Giulia, Zaman, Burhan Abdullah, Zaman, Sojib Bin, Zamora, Nelson, Zand, Ramin, Zandi, Milad, Zandieh, Ghazal G Z, Zanghì, Aurora, Zare, Iman, Zastrozhin, Mikhail Sergeevich, Zeariya, Mohammed G M, Zeng, Youjie, Zhai, Chunxia, Zhang, Chen, Zhang, Haijun, Zhang, Hongwei, Zhang, Yunquan, Zhang, Zhaofeng, Zhang, Zhenyu, Zhao, Hanqing, Zhao, Yang, Zhao, Yong, Zheng, Peng, Zhong, Chenwen, Zhou, Juexiao, Zhu, Bin, Zhu, Zhaohua, Ziaeefar, Pardis, Zielińska, Magdalena, Zou, Zhiyong, Zumla, Alimuddin, Zweck, Elric, Zyoud, Samer H, Lim, Stephen S, and Murray, Christopher J L
- Abstract
Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period.
- Published
- 2024
- Full Text
- View/download PDF
14. Assisted reproductive techniques and subsequent risk of asthma and allergic rhinitis in offspring: a nationwide birth cohort study in South Korea.
- Author
-
KIM, S. H., KIM, M., LEE, H., WOO, S., KIM, H. J., KOYANAGI, A., SMITH, L., KIM, M. S., MIN, H. K., MIN, J.-Y., and YON, D. K.
- Abstract
OBJECTIVE: The relationship between assisted reproductive techniques (ART) and the risk of asthma and allergic rhinitis (AR) is controversial. Thus, we aimed to investigate the relationship between ART and the risk of asthma and AR in a nationwide, largescale birth cohort. PATIENTS AND METHODS: This study utilized the National Health Insurance Service data in South Korea to conduct a nationwide, largescale, population-based birth cohort. We included all infants born between 2017 and 2018. AR, asthma, food allergies, and atopic dermatitis were defined using the International Classification of Diseases tenth edition codes. Asthma was classified as allergic or non-allergic based on accompanying allergic diseases (AR, food allergy, or atopic dermatitis). Using 1:10 propensity score matching, we compared infants conceived through ART with those conceived naturally (non-ART). After matching, logistic regression was used to compare the hazard ratio for asthma and AR between the two groups. RESULTS: We included 543,178 infants [male infants, 280,194 (51.38%)]. After matching, 8,925 and 74,229 infants were selected for the ART and non-ART groups, respectively. The ART group showed a decreased risk of asthma in the offspring [adjusted hazard ratio (aHR), 0.45; 95% confidence interval (CI), 0.41-0.48]. Similarly, for AR, being conceived by ART was associated with a decreased risk of AR (aHR, 0.25; 95% CI, 0.12-0.37). ART offspring showed a decreased risk of asthma and AR in offspring compared to that observed in non-ART offspring. CONCLUSIONS: Our study offers important insights for clinicians, researchers, and parents regarding the health outcomes of ART-conceived infants and enhances our understanding of ART's impact on respiratory health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
15. A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
- Author
-
Tsushima, Takahiro, Hironaka, Shuichi, Tsubosa, Yasuhiro, Kato, Ken, Nomura, Motoo, Hara, Hiroki, Kitagawa, Yuko, Koyanagi, Kazuo, Kajiwara, Takeshi, Takegawa, Naoki, Matsubara, Hisahiro, Baba, Hideo, Morita, Masaru, Masuzawa, Toru, Hasegawa, Hiroko, Kojima, Takashi, Machida, Ryunosuke, Sasaki, Keita, TAKEUCHI, HIROYA, and Kadowaki, Shigenori
- Published
- 2024
- Full Text
- View/download PDF
16. An observational study on treatment patterns and outcomes among patients with metastatic or recurrent esophageal cancer: Real-world data and empirical analyses in Japan (POME).
- Author
-
Yamamoto, Shun, Kato, Ken, Saeki, Hiroshi, Kadowaki, Shigenori, Minashi, Keiko, Kasahara, Yuki, Nomura, Motoo, Yasuda, Tomoyo, Sato, Yusuke, Koyanagi, Kazuo, Izawa, Naoki, Okada, Morihito, Satake, Hironaga, Morita, Shuko, Goto, Masahiro, Yoshii, Takako, Yamamoto, Sachiko, Izawa, Makiko, Uemura, Kohei, and Muro, Kei
- Published
- 2024
- Full Text
- View/download PDF
17. A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial).
- Author
-
TAKEUCHI, HIROYA, Ando, Masahiko, Tsubosa, Yasuhiro, Kikuchi, Hirotoshi, Kawakubo, Hirofumi, Noma, Kazuhiro, Ueno, Masaki, Tsushima, Takahiro, Bamba, Takeo, Fujita, Takeo, Hamai, Yoichi, Kakishita, Tomokazu, Daiko, Hiroyuki, Koyanagi, Kazuo, Matsuda, Satoru, Kato, Ken, Sasaki, Keita, Kita, Ryosuke, Machida, Ryunosuke, and Kitagawa, Yuko
- Published
- 2024
- Full Text
- View/download PDF
18. Prevalence of sarcopenia in Africa: a systematic review and meta-analysis of observational studies.
- Author
-
Veronese, Nicola, Smith, Lee, Koyanagi, Ai, Hoffman, Jaco, Snoussi, Mouna, Prokopidis, Konstantinos, Dominguez, Ligia J., and Barbagallo, Mario
- Abstract
Background: Existing literature suggests that sarcopenia is a highly prevalent condition in older people. However, most studies to date reporting data on its prevalence have been mainly carried out in Western countries, while data on sarcopenia in Africa is scarce. With this systematic review and meta‐analysis, we aimed to determine the prevalence of sarcopenia in African countries and to explore potential factors that could explain higher or lower prevalence of this condition in Africa. Methods: Major databases for studies reporting data on sarcopenia in African countries were searched from inception to June 2023. We conducted a meta-analysis of the prevalence [and 95% confidence intervals (95% CIs)] of sarcopenia in Africa, applying a random effect model. Several sensitivity and meta-regression analyses were run. Results: Among 147 articles initially screened, six articles (with seven cohorts) including a total of 10,656 participants were included. Mean age of participants was 66.9 years, and the majority were female (58.1%). The weighted prevalence of sarcopenia in the selected countries of Africa was 25.72% (95%CI: 18.90–32.55). This outcome was characterized by a high heterogeneity (I
2 = 99%) and by publication bias. Among the factors investigated, sarcopenia was lower when assessed using only one anthropometric measure, or in South Africa. Conclusion: Sarcopenia is a prevalent condition in Africa and thus research regarding this topic is a public health priority. Future studies that cover African countries for which data are not available and using standardized criteria are needed. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
19. Pipeline embolization device dynamics: prediction of incomplete occlusion by elongation from nominal length.
- Author
-
Tadashi Sunohara, Hirotoshi Imamura, Tsuyoshi Ohta, Masaomi Koyanagi, Masanori Goto, Ryu Fukumitsu, Nobuyuki Fukui, Yuuki Takano, Yoshinori Matsuoka, Kunimasa Teranishi, Yuuji Naramoto, Yasuhiro Yamamoto, Rikuo Nishii, Chiaki Sakai, and Nobuyuki Sakai
- Published
- 2024
- Full Text
- View/download PDF
20. National long-term trends in health-related quality of life using EQ-5D-3L in South Korea, 2008-2021, including the COVID-19 pandemic: a representative serial study of 2.8 million people.
- Author
-
KIM, H., KIM, M., RHEE, S. Y., KOYANAGI, A., SMITH, L., KIM, M. S., FOND, G., BOYER, L., KIM, S., SHIN, J. I., JACOB, L., LEE, J., RAHMATI, M., YEO, S. G., and YON, D. K.
- Abstract
OBJECTIVE: There is a scarcity of literature investigating the impact of the coronavirus disease 2019 (COVID-19) pandemic on long-term trends in health-related quality of life (HrQoL) using large-scale and representative data. Thus, we aimed to investigate the nationwide and long-term trends in quality of life (QoL) using the European Quality of Life-5 dimensions, 3-level version (EQ-5D-3L) from a Korean representative serial study of 2.8 million people, 2008-2021. SUBJECTS AND METHODS: This Korean study used data on adults between 2008 and 2021 who participated in the Community Health Survey. Timeframes were categorized as COVID-19 mid-pandemic (2021) and pre-pandemic (2008-2019). The mean EQ-5D-3L index for the whole population and subgroups stratified by demographic characters was evaluated for each timeframe, and differences between before and during the COVID-19 pandemic were also analyzed. RESULTS: 2,827,240 adults who responded to the survey, 2008-2021, were eligible for this study. Overall EQ-5D index persistently decreased from 2008-2016, then minimally decreased during the pandemic, still being much higher than forecasted before the COVID-19 pandemic. The reduction in the rate of decline in QoL after the COVID-19 outbreak was especially marked in white-collared, young adults, people with 'good' or 'very good' subjective health, and college-educated or above group. On the other hand, the previously increasing trend of QoL in the elderly group has decelerated during the pandemic, and QoL of the 'very bad' subjective health group recorded the lowest among the whole study period. CONCLUSIONS: The present study investigated the long-term trend of QoL in Korean adults using serial data over the past 14 years, with a special emphasis on comparing the preand mid-COVID-19 pandemic periods. [ABSTRACT FROM AUTHOR]
- Published
- 2024
21. National trends in the prevalence of hepatitis B and C in South Korea, before and during the COVID-19 pandemic (2007-2021) – a nationwide representative study.
- Author
-
PARK, J.-J., LEE, M., KIM, H., PARK, J.-Y., LEE, H., KIM, H. J., KOYANAGI, A., SMITH, L., KIM, M. S., RAHMATI, M., RHEE, S. Y., HA, Y., LEE, K., and YON, D. K.
- Abstract
OBJECTIVE: Due to the various changes caused by the COVID-19 pandemic, some infectious diseases showed different epidemiology and prevalence during the pandemic. However, there is a lack of comprehensive studies on trends in the prevalence of hepatitis B and C related to the pandemic. Thus, we compared the prevalence of hepatitis B and C before and during the COVID-19 pandemic in South Korea. SUBJECTS AND METHODS: We conducted a comprehensive trend analysis with a nationwide serial cross-sectional survey from 2007 to 2021 (n=86,931) using the Korea National Health and Nutrition Examination Survey (KNHANES). The changes in the prevalence of hepatitis B and C were evaluated using a weighted regression model to assess the impact of the COVID-19 pandemic. RESULTS: From 2007 to 2021, 86,931 Korean adults aged 19 or older were included in the KNHANES data. The prevalence of hepatitis B showed a declining trend until the onset of the pandemic (1.80% in 2007-2009; 1.08% in 2016-2019; and 1.01% in 2020), at which point this trend reversed (1.39% in 2021). The prevalence of hepatitis C remained stable (0.14% in 2007-2009 and 0.18% in 2016-2019), with no particular surge related to the COVID-19 pandemic (βdiff, -0.002; 95% CI, -0.761 to 0.756). For hepatitis B, old age was identified as a pandemic-related vulnerable factor (ratio of odds ratio, 1.68; 95% CI, 1.05-2.70). CONCLUSIONS: In this study, unlike other infectious diseases, hepatitis B and C did not show a decreasing trend during the pandemic. In particular, hepatitis B showed a rebound trend during the pandemic, which was noticeable in those aged 60 or older. Further studies are needed to support these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
22. Effects and safety of transcranial direct current stimulation on multiple health outcomes: an umbrella review of randomized clinical trials
- Author
-
Kang, Jiseung, Lee, Hyeri, Yu, Seungyeong, Lee, Myeongcheol, Kim, Hyeon Jin, Kwon, Rosie, Kim, Sunyoung, Fond, Guillaume, Boyer, Laurent, Rahmati, Masoud, Koyanagi, Ai, Smith, Lee, Nehs, Christa J., Kim, Min Seo, Sánchez, Guillermo F. López, Dragioti, Elena, Kim, Tae, and Yon, Dong Keon
- Abstract
Transcranial direct current stimulation (tDCS), which delivers a direct current to the brain, emerged as a non-invasive potential therapeutic in treating a range of neurological and neuropsychiatric disorders. However, a comprehensive quantitative evidence synthesis on the effects of tDCS on a broad range of mental illnesses is lacking. Here, we systematically assess the certainty of the effects and safety of tDCS on several health outcomes using an umbrella review of randomized controlled trials (RCTs). The methodological quality of each included original meta-analysis was assessed by the A Measurement Tool for Assessing Systematic Reviews 2 (AMSTAR2), and the certainty of the evidence for each effect was evaluated with Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). We followed an a priori protocol (PROSPERO CRD42023458700). We identified 15 meta-analyses of RCTs (AMSTAR 2; high 3, moderate 3, and low 9) that included 282 original articles, covering 22 unique health endpoints across 22 countries and six continents. From meta-analyses of RCTs supported by very low to high certainty of evidence, it was found that tDCS improved symptoms related to post-stroke, including post-stroke depression scale score (equivalent standardized mean difference [eSMD], 1.61 [95% confidence level, 0.72–2.50]; GRADE=moderate), activities of daily living independence (7.04 [3.41–10.67]; GRADE=high), motor recovery of upper and lower extremity (upper extremity: 0.15 [0.06–0.24], GRADE=high; lower extremity: 0.10 [0.03–0.16], GRADE=high), swallowing performance (GRADE=low), and spasticity (GRADE=moderate). In addition, tDCS had treatment effects on symptoms of several neurological and neuropsychiatric disorders, including obsessive-compulsive disorder (0.81 [0.44–1.18]; GRADE=high), pain in fibromyalgia (GRADE=low), disease of consciousness (GRADE=low), insight score (GRADE=moderate) and working memory (0.34 [0.01-0.67]; GRADE=high) in schizophrenia, migraine-related pain (−1.52 [−2.91 to −0.13]; GRADE=high), attention-deficit/hyperactivity disorder (reduction in overall symptom severity: 0.24 [0.04–0.45], GRADE=low; reduction in inattention: 0.56 [0.02–1.11], GRADE=low; reduction in impulsivity: 0.28 [0.04–0.51], GRADE=low), depression (GRADE=low), cerebellar ataxia (GRADE=low), and pain (GRADE=very low). Importantly, tDCS induced an increased number of reported cases of treatment-emergent mania or hypomania (0.88 [0.62–1.13]; GRADE=moderate). We found varied levels of evidence for the effects of tDCS with multiple neurological and neuropsychiatric conditions, from very low to high certainty of evidence. tDCS was effective for people with stroke, obsessive-compulsive disorder, fibromyalgia, disease of consciousness, schizophrenia, migraine, attention-deficit/hyperactivity disorder, depression, cerebellar ataxia, and pain. Therefore, these findings suggest the benefit of tDCS for several neurological and neuropsychiatric disorders; however, further studies are needed to understand the underlying mechanism and optimize its therapeutic potential.
- Published
- 2024
- Full Text
- View/download PDF
23. Disease-specific variant interpretation highlighted the genetic findings in 2325 Japanese patients with retinitis pigmentosa and allied diseases
- Author
-
Goto, Kensuke, Koyanagi, Yoshito, Akiyama, Masato, Murakami, Yusuke, Fukushima, Masatoshi, Fujiwara, Kohta, Iijima, Hanae, Yamaguchi, Mitsuyo, Endo, Mikiko, Hashimoto, Kazuki, Ishizu, Masataka, Hirakata, Toshiaki, Mizobuchi, Kei, Takayama, Masakazu, Ota, Junya, Sajiki, Ai Fujita, Kominami, Taro, Ushida, Hiroaki, Fujita, Kosuke, Kaneko, Hiroki, Ueno, Shinji, Hayashi, Takaaki, Terao, Chikashi, Hotta, Yoshihiro, Murakami, Akira, Kuniyoshi, Kazuki, Kusaka, Shunji, Wada, Yuko, Abe, Toshiaki, Nakazawa, Toru, Ikeda, Yasuhiro, Momozawa, Yukihide, Sonoda, Koh-Hei, and Nishiguchi, Koji M
- Abstract
BackgroundAs gene-specific therapy for inherited retinal dystrophy (IRD) advances, unified variant interpretation across institutes is becoming increasingly important. This study aims to update the genetic findings of 86 retinitis pigmentosa (RP)-related genes in a large number of Japanese patients with RP by applying the standardised variant interpretation guidelines for Japanese patients with IRD (J-IRD-VI guidelines) built upon the American College of Medical Genetics and Genomics and the Association for Molecular Pathology rules, and assess the contribution of these genes in RP–allied diseases.MethodsWe assessed 2325 probands with RP (n=2155, including n=1204 sequenced previously with the same sequencing panel) and allied diseases (n=170, newly analysed), including Usher syndrome, Leber congenital amaurosis and cone-rod dystrophy (CRD). Target sequencing using a panel of 86 genes was performed. The variants were interpreted according to the J-IRD-VI guidelines.ResultsA total of 3564 variants were detected, of which 524 variants were interpreted as pathogenic or likely pathogenic. Among these 524 variants, 280 (53.4%) had been either undetected or interpreted as variants of unknown significance or benign variants in our earlier study of 1204 patients with RP. This led to a genetic diagnostic rate in 38.6% of patients with RP, with EYSaccounting for 46.7% of the genetically solved patients, showing a 9% increase in diagnostic rate from our earlier study. The genetic diagnostic rate for patients with CRD was 28.2%, with RP-related genes significantly contributing over other allied diseases.ConclusionA large-scale genetic analysis using the J-IRD-VI guidelines highlighted the population-specific genetic findings for Japanese patients with IRD; these findings serve as a foundation for the clinical application of gene-specific therapies.
- Published
- 2024
- Full Text
- View/download PDF
24. Association between self-reported visual symptoms (suggesting cataract) and self-reported fall-related injury among adults aged ≥ 65 years from five low- and middle-income countries
- Author
-
Smith, Lee, López Sánchez, Guillermo F., Veronese, Nicola, Soysal, Pinar, Tully, Mark A., Gorely, Trish, Allen, Peter M., Rahmati, Masoud, Yon, Dong Keon, Ball, Graham, Butler, Laurie, Keyes, Helen, Barnett, Yvonne, Shin, Jae Il, and Koyanagi, Ai
- Abstract
Background: Cataracts may increase risk for falls but studies on this topic from low- and middle-income countries (LMICs) are scarce. Therefore, we examined the cross-sectional association between self-reported visual symptoms (suggesting cataract) and self-reported injurious falls in nationally representative samples of adults aged ≥ 65 years from five LMICs (China, Ghana, India, Mexico, and Russia). Methods: Data from the WHO Study on global AGEing and adult health (SAGE) were analysed. Self-reported information on past 12-month fall-related injury and cataract based on symptoms were collected. Multivariable logistic regression and meta-analyses were conducted to assess associations. Results: Data on 13,101 people aged ≥ 65 years were analysed [mean (SD) age 72.5 (11.3) years; 45.2% males]. The overall prevalence of self-reported fall-related injury and visual symptoms (suggesting cataract) were 4.9% and 29.4%, respectively. There was a positive association between self-reported visual symptoms (suggesting cataract) and fall-related injury (i.e., OR > 1) in all five countries but statistical significance was reached in three: China (OR = 1.60; 95% CI = 1.08–2.35), India (OR = 1.96; 95% CI = 1.15–3.35), and Russia (OR = 3.58; 95% CI = 2.06–6.24). The pooled OR including all five countries based on a meta-analysis was OR = 1.88 (95% CI = 1.32–2.68). Conclusions: Self-reported visual symptoms (suggesting cataract) were associated with higher odds for self-reported injurious falls among older adults in LMICs. Expanding availability of cataract surgery in LMICs may also have the additional benefit of reducing falls among older people.
- Published
- 2024
- Full Text
- View/download PDF
25. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study
- Author
-
Cortese, Samuele, Song, Minjin, Farhat, Luis C., Yon, Dong Keon, Lee, Seung Won, Kim, Min Seo, Park, Seoyeon, Oh, Jae Won, Lee, San, Cheon, Keun-Ah, Smith, Lee, Gosling, Corentin J., Polanczyk, Guilherme V., Larsson, Henrik, Rohde, Luis A., Faraone, Stephen V., Koyanagi, Ai, Dragioti, Elena, Radua, Joaquim, Carvalho, Andre F., Il Shin, Jae, and Solmi, Marco
- Abstract
Data on incidence, prevalence and burden of ADHD are crucial for clinicians, patients, and stakeholders. We present the incidence, prevalence, and burden of ADHD globally and across countries from 1990 to 2019 from the Global Burden of Disease (GBD) study. We also: (1) calculated the ADHD prevalence based on data actually collected as opposed to the prevalence estimated by the GBD with data imputation for countries without prevalence data; (2) discussed the GBD estimated ADHD burden in the light of recent meta-analytic evidence on ADHD-related mortality. In 2019, GBD estimated global age-standardized incidence and prevalence of ADHD across the lifespan at 0.061% (95%UI = 0.040–0.087) and 1.13% (95%UI = 0.831–1.494), respectively. ADHD accounted for 0.8% of the global mental disorder DALYs, with mortality set at zero by the GBD. From 1990 to 2019 there was a decrease of −8.75% in the global age-standardized prevalence and of −4.77% in the global age-standardized incidence. The largest increase in incidence, prevalence, and burden from 1990 to 2019 was observed in the USA; the largest decrease occurred in Finland. Incidence, prevalence, and DALYs remained approximately 2.5 times higher in males than females from 1990 to 2019. Incidence peaked at age 5–9 years, and prevalence and DALYs at age 10–14 years. Our re-analysis of data prior to 2013 showed a prevalence in children/adolescents two-fold higher (5.41%, 95% CI: 4.67–6.15%) compared to the corresponding GBD estimated prevalence (2.68%, 1.83–3.72%), with no significant differences between low- and middle- and high-income countries. We also found meta-analytic evidence of significantly increased ADHD-related mortality due to unnatural causes. While it provides the most detailed evidence on temporal trends, as well as on geographic and sex variations in incidence, prevalence, and burden of ADHD, the GBD may have underestimated the ADHD prevalence and burden. Given the influence of the GBD on research and policies, methodological issues should be addressed in its future editions.
- Published
- 2023
- Full Text
- View/download PDF
26. Predictors of Progression-Free Survival in Patients With Spinal Intramedullary Ependymoma: A Multicenter Retrospective Study by the Neurospinal Society of Japan
- Author
-
Naito, Kentaro, Umebayashi, Daisuke, Kurokawa, Ryu, Endo, Toshiki, Mizuno, Masaki, Hoshimaru, Minoru, Kim, Phyo, Hida, Kazutoshi, Takami, Toshihiro, Hara, Masahito, Aoyama, Masahiro, Sugawara, Taku, Shimizu, Hiroaki, Ogihara, Kotaro, Sugawara, Atsushi, Itoki, Kazushige, Matsui, Seiji, Shigekawa, Seiji, Kunihiro, Noritsugu, Yamamoto, Shinji, Yasuhara, Takao, Iwasaki, Motoyuki, Ueda, Shigeo, Miyoshi, Yasuyuki, Hayashi, Hideki, Noriyuki, Nakayama, Iwama, Toru, Nakagawa, Hiroshi, Sumiyoshi, Manabu, Hijikata, Yasukazu, Uchikado, Hisaaki, Fukuda, Hitoshi, Nakai, Tomoaki, Sasayama, Takashi, Mishima, Kazuhiko, Inoue, Tomoo, Yano, Shunsuke, Sasamori, Toru, Mikuni, Nobuhiro, Akiyama, Yukinori, Hara, Tsuyoshi, Gondo, Gakuji, Yoshida, Mitsuhiro, Komatani, Hideki, Takahashi, Yuichi, Ito, Kiyoshi, Goto, Hisaharu, Yasuhiro, Node, Watanabe, Mizuki, Ito, Yasunobu, Hirano, Yoshitaka, Tominaga, Teiji, Takami, Hirokazu, Karakama, Jun, Ohashi, Hiroki, Harada, Naoyuki, Shingo, Tetsuro, Kawajiri, Satoshi, Yamauchi, Tomohiro, Uno, Tetsuji, Takai, Keisuke, Fujimoto, So, Otake, Yasufumi, Takeshima, Yasuhiro, Nakase, Hiroyuki, Saito, Akihiko, Morimoto, Daijiro, Kim, Kyongsong, Ohtonari, Tatsuya, Kageyama, Hiroto, Mitsuhara, Takafumi, Kuromi, Yosuke, Takahashi, Toshiyuki, Kanematsu, Ryo, Inoue, Tatsushi, Seki, Toshitaka, Yamazaki, Kazuyoshi, Koyanagi, Izumi, Yoshifuji, Kazuhisa, Fujimoto, Masashi, Nishikawa, Misao, Yagi, Takashi, Kinouchi, Hiroyuki, Murata, Hidetoshi, and Kitayama, Mari
- Published
- 2023
- Full Text
- View/download PDF
27. Potential Effects of Alpha-Glycosyl Isoquercitrin on Memory by Altering the Gut Microbiota-Blood–Brain Axis in Mice
- Author
-
Liu, Hong, Inoue, Ryo, Koyanagi, Mihoko, Hayashi, Shim-mo, and Nagaoka, Kentaro
- Abstract
Alpha-glycosyl isoquercitrin (AGIQ), composed of isoquercitrin and glycosylated quercetin, has multiple biological effects. Here, we further examined the influence of AGIQ on brain function and provided its potential mechanism. Male C57BL/6 mice were treated with 0, 0.005, and 0.05% AGIQ in drinking water for 4 weeks prior to behavioral testing. Behavior tests showed that 0.05% AGIQ treatment significantly improved learning and memory function without affecting emotion. In the hippocampus, the gene expression of antioxidative defense enzymes was upregulated after 0.05% AGIQ treatment. In contrast, AGIQ caused significant alterations in the microbial abundance of genera Akkermansia, Bifidobacterium, and Alistipesassociated with memory function. Metabolomics analysis identified that taurine concentration was significantly increased in serum and hippocampus from AGIQ-treated mice. The correlation analysis suggested that elevated serum taurine levels were closely related to the abundance of Akkermansia, indicating the underlying crosstalk of gut microbiota and serum metabolites. In vitro fecal culture further demonstrated that AGIQ could increase the level of Akkermansia. Taurine could exert antioxidant activity in SH-SY5Y neuroblastoma cell lines in vitro. Finally, vancomycin-induced alterations of gut microbiota attenuated the taurine increases in the serum and the antioxidant gene level in the hippocampus by AGIQ. Taken together, it is likely that AGIQ could increase genus Akkermansiaabundance and ultimately increase taurine levels in serum and hippocampus to improve learning and memory function, relying on the gut microbiota-blood–brain axis. Our results supply a new view for understanding effects of AGIQ on brain function.
- Published
- 2023
- Full Text
- View/download PDF
28. The global, regional, and national burden of inflammatory bowel diseases, 1990–2019: A systematic analysis for the global burden of disease study 2019.
- Author
-
Park, Jihye, Jeong, Gwang Hun, Song, Minjin, Yon, Dong Keon, Lee, Seung Won, Koyanagi, Ai, Jacob, Louis, Kostev, Karel, Dragioti, Elena, Radua, Joaquim, Cheon, Jae Hee, Shin, Jae Il, and Smith, Lee
- Abstract
In recent years, the global epidemiology of inflammatory bowel disease (IBD) has changed rapidly. We described the updated global IBD epidemiology results based on the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). We estimated the prevalence rate, death rate, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) from GBD 2019 in 195 countries and territories between 1990 and 2019. The crude prevalence of IBD increased by 47% in 2019 globally. Accordingly, the age-standardized prevalence rate showed 19% decrease. The age-standardized death rates, YLDs, YLLs, and DALYs of IBD in 2019 decreased compared to those in 1990. The annual percentage change in age-standardized prevalence rate decreased most in United States and increased in East Asia and high-income Asia Pacific from 1990 to 2019. Continents with high socioeconomic index (SDI) had higher age-standardized prevalence rates compared to continents with low SDI. The 2019 age-standardized prevalence rate of high latitudes was higher than that of low latitudes in Asia, Europe, and North America. The observed trends and geographic variations in IBD documented in the 2019 GBD study will aid policymakers in policy, research, and investment development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Temporal Trends in Bullying Victimization Among Adolescents Aged 12–15 Years From 29 Countries: A Global Perspective.
- Author
-
Smith, Lee, López Sánchez, Guillermo F., Haro, Josep Maria, Alghamdi, Abdullah Ahmed, Pizzol, Damiano, Tully, Mark A., Oh, Hans, Gibson, Poppy, Keyes, Helen, Butler, Laurie, Barnett, Yvonne, Shin, Jae Il, and Koyanagi, Ai
- Abstract
Bullying victimization among adolescents is a major public health concern. However, multicountry studies investigating temporal trends of bullying victimization among adolescents are scarce, especially from a global perspective. Thus, we aimed to examine the temporal trends of bullying victimization among school-going adolescents between 2003 and 2017 in 29 countries from Africa (n = 5), Asia (n = 18), and the Americas (n = 6). Data on 191,228 students aged 12–15 years [mean (standard deviation) age 13.7 (1.0) years; 48.9% boys] who participated in the Global School-based Student Health Survey were analyzed. Bullying victimization was based on self-report and referred to being bullied at least once in the past 30 days. The prevalence (95% confidence interval) of bullying victimization was calculated for each survey. Crude linear trends in bullying victimization were examined by linear regression models. The mean prevalence of bullying victimization across all surveys was 39.4%. There was a large variation in the trends of bullying victimization across countries with a significant increasing and decreasing trend being observed in 6 and 13 countries, respectively. Myanmar, Egypt, and the Philippines showed the sharpest increase. The decrease was modest in most countries which showed a decreasing trend. The remaining countries showed stable trends (n = 10) but some countries such as Seychelles showed consistently high prevalence over time (i.e., ≥ 50%). Decreasing trends of bullying victimization were more common than increasing or stable trends in our study including adolescents from 29 countries. However, a high prevalence of bullying was observed in most countries, and thus, further global efforts to combat bullying victimization are necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Dynapenic abdominal obesity and incident multimorbidity: findings from the English longitudinal study on ageing.
- Author
-
Veronese, Nicola, Koyanagi, Ai, Soysal, Pinar, Sapienza, Vitalba, Ragusa, Francesco Saverio, Bolzetta, Francesco, Dominguez, Ligia J., Barbagallo, Mario, and Smith, Lee
- Abstract
Background: Dynapenic abdominal obesity (DAO) (i.e., impairment in muscle strength and high waist circumference) is gaining interest, as it is associated with several important adverse health outcomes. However, the association between DAO and multimorbidity is largely unclear. Thus, the aim of the present study was to investigate the association between DAO at baseline and new onset multimorbidity over ten years of follow-up. Methods: People participating in the English Longitudinal Study of Ageing were included. DAO was defined as waist circumference > 102 cm in men and > 88 cm in women, and a concomitant presence of dynapenia (handgrip strength defined as < 27 kg for men and < 16 kg for women). Multimorbidity was defined as having two or more chronic conditions. The association between DAO and incident multimorbidity was assessed using a multivariable logistic regression analysis, reporting the data as odds ratios (ORs) and their 95% confidence intervals (CIs). Results: Overall, 3302 participants (mean age: 63.4 years, males: 50.3%) without multimorbidity at baseline were followed-up for ten years. After adjusting for several variables, compared to participants without dynapenia nor abdominal obesity, the presence of abdominal obesity (OR = 1.505; 95%CI: 1.272–1.780; p < 0.0001) and DAO (OR = 1.671; 95%CI: 1.201–2.325; p = 0.002) significantly increased the risk of multimorbidity. Compared to no dynapenia nor abdominal obesity, DAO was associated with significantly higher risk for arthritis and diabetes. Conclusions: DAO was significantly associated with a higher risk of incident multimorbidity, over 10 years of follow-up. The results of our study suggest that addressing DAO can potentially decrease risk for multimorbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Pain and mild cognitive impairment among adults aged 50 years and above residing in low- and middle-income countries.
- Author
-
Smith, Lee, López Sánchez, Guillermo F., Shin, Jae Il, Soysal, Pinar, Pizzol, Damiano, Barnett, Yvonne, Kostev, Karel, Jacob, Louis, Veronese, Nicola, Butler, Laurie, Odell-Miller, Helen, Bloska, Jodie, Underwood, Benjamin R., and Koyanagi, Ai
- Abstract
Background: Previous studies on the association between pain and cognitive decline or impairment have yielded mixed results, while studies from low- and middle-income countries (LMICs) or specifically on mild cognitive impairment (MCI) are scarce. Thus, we investigated the association between pain and MCI in LMICs and quantified the extent to which perceived stress, sleep/energy problems, and mobility limitations explain the pain/MCI relationship. Methods: Data analysis of cross-sectional data from six LMICs from the Study on Global Ageing and Adult Health (SAGE) were performed. MCI was based on the National Institute on Aging-Alzheimer's Association criteria. "Overall in the last 30 days, how much of bodily aches or pain did you have?" was the question utilized to assess pain. Associations were examined by multivariable logistic regression analysis and meta-analysis. Results: Data on 32,715 individuals aged 50 years and over were analysed [mean (SD) age 62.1 (15.6) years; 51.7% females]. In the overall sample, compared to no pain, mild, moderate, and severe/extreme pain were dose-dependently associated with 1.36 (95% CI = 1.18–1.55), 2.15 (95% CI = 1.77–2.62), and 3.01 (95% CI = 2.36–3.85) times higher odds for MCI, respectively. Mediation analysis showed that perceived stress, sleep/energy problems, and mobility limitations explained 10.4%, 30.6%, and 51.5% of the association between severe/extreme pain and MCI. Conclusions: Among middle-aged to older adults from six LMICs, pain was associated with MCI dose-dependently, and sleep problems and mobility limitations were identified as potential mediators. These findings raise the possibility of pain as a modifiable risk factor for developing MCI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Differences in Pandemic-Related Factors Associated with Alcohol and Substance Use among Korean Adolescents: Nationwide Representative Study*.
- Author
-
Yon, Hyunju, Park, Sangil, Shin, Jung U, Koyanagi, Ai, Jacob, Louis, Smith, Lee, Min, Chanyang, Lee, Jinseok, Kwon, Rosie, Fond, Guillaume, Boyer, Laurent, Kim, Sunyoung, Kim, Namwoo, Rhee, Sang Youl, Shin, Jae Il, Yon, Dong Keon, and Woo, Ho Geol
- Subjects
KOREANS ,SUBSTANCE abuse ,BEVERAGES - Published
- 2023
- Full Text
- View/download PDF
33. Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.
- Author
-
Watanabe, Shinya, Nonaka, Takahiro, Maeda, Makoto, Sugii, Narushi, Hashimoto, Koichi, Takano, Shingo, Koyanagi, Tomoyoshi, Yamada, Masanobu, Arakawa, Yoshihiro, and Ishikawa, Eiichi
- Subjects
TREATMENT effectiveness ,MENINGIOMA ,DESCRIPTIVE statistics ,RESEARCH funding ,PROGRESSION-free survival ,OVERALL survival ,EVALUATION - Abstract
Background: Response Evaluation Criteria in Solid Tumors (RECIST)-based response rates are commonly used as efficacy endpoints in phase II clinical trials for solid tumors. However, no consensus has been reached concerning adequate efficacy endpoints for phase II clinical trials targeting meningioma. Irregularity of lesions after resection, and varying degrees of dysplasia and histologic subtypes make establishing an appropriate efficacy evaluation difficult. Methods: We analyzed primary efficacy endpoints (PEEs) and background factors from 48 trials retrieved from ClinicalTrials.gov (https://clinicaltrials.gov/) using the search criteria "meningioma," "interventional," "phase II," and "study start 4/1/2001 to 3/31/2021." Primary purpose of the study was efficacy endpoint setting in overall population and three subgroups. Results: Among 45 PEEs set in the 39 trials included; 33 trials with single PEE, and six trials with double PEEs, 17/45 (38%) trials adopted progression-free survival (PFS) rate, 15/45 (33%) trials response rate (seven Macdonald criteria or modified, three RECIST, three volumetric estimation, one RANO criteria, one unknown), 10/45 (22%) PFS, 1/45 (2%) OS, and 2/45 (4%) other endpoints. Although 26 PEEs were time-to-event endpoints, 19 of the 26 PEEs were single-arm studies. Conclusions: Time-to-event efficacy endpoints were often compared to historical data, and two-dimensional evaluation is more suitable than one-dimensional one. Accumulation of prognostic data is essential to standardize time-to-event efficacy endpoints. Considering the difficulty of setting design for phase II clinical studies targeting meningioma, evaluation might be done with multiple efficacy endpoints. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Predicting the growth of middle cerebral artery bifurcation aneurysms using differences in the bifurcation angle and inflow coefficient.
- Author
-
Takeshi Miyata, Hiroharu Kataoka, Kampei Shimizu, Akihiro Okada, Takanobu Yagi, Hirotoshi Imamura, Masaomi Koyanagi, Ryota Ishibashi, Masanori Goto, Nobuyuki Sakai, Taketo Hatano, Masaki Chin, Koichi Iwasaki, and Susumu Miyamoto
- Published
- 2023
- Full Text
- View/download PDF
35. Validation of the CompactDry “Nissui” BC for Enumeration of Bacillus cereusin a Variety of Foods: AOAC Performance Tested MethodSM092201
- Author
-
Koyanagi, Yusuke, Yamazaki, Tomoki, and Betts, Gail
- Published
- 2023
- Full Text
- View/download PDF
36. Isolated small ventricular septal defects in utero: HDliveFlow with spatiotemporal image correlation and HDliveSilhouette case study
- Author
-
Hata, Toshiyuki, Kawahara, Tomomi, Konishi, Miyu, Bouno, Saori, Yamanishi, Tomomi, Koyanagi, Aya, and Miyake, Takahito
- Abstract
To demonstrate shunt flow through small ventricular septal defects (VSDs) using HDlive Flow with spatiotemporal image correlation (STIC) and HDlive Silhouette. Four cases of isolated small VSDs were evaluated using colour Doppler, and HDlive Flow with STIC and HDlive Silhouette. HDlive Flow with STIC and HDlive Silhouette can improve the ability to depict shunt flow through small VSDs compared with colour Doppler. This technique provides information on spatial recognition of the shunt flow through isolated small VSDs in real time.
- Published
- 2023
- Full Text
- View/download PDF
37. Dynapenic abdominal obesity and incident multimorbidity: findings from the English longitudinal study on ageing
- Author
-
Veronese, Nicola, Koyanagi, Ai, Soysal, Pinar, Sapienza, Vitalba, Ragusa, Francesco Saverio, Bolzetta, Francesco, Dominguez, Ligia J., Barbagallo, Mario, and Smith, Lee
- Abstract
Background: Dynapenic abdominal obesity (DAO) (i.e., impairment in muscle strength and high waist circumference) is gaining interest, as it is associated with several important adverse health outcomes. However, the association between DAO and multimorbidity is largely unclear. Thus, the aim of the present study was to investigate the association between DAO at baseline and new onset multimorbidity over ten years of follow-up. Methods: People participating in the English Longitudinal Study of Ageing were included. DAO was defined as waist circumference > 102 cm in men and > 88 cm in women, and a concomitant presence of dynapenia (handgrip strength defined as < 27 kg for men and < 16 kg for women). Multimorbidity was defined as having two or more chronic conditions. The association between DAO and incident multimorbidity was assessed using a multivariable logistic regression analysis, reporting the data as odds ratios (ORs) and their 95% confidence intervals (CIs). Results: Overall, 3302 participants (mean age: 63.4 years, males: 50.3%) without multimorbidity at baseline were followed-up for ten years. After adjusting for several variables, compared to participants without dynapenia nor abdominal obesity, the presence of abdominal obesity (OR = 1.505; 95%CI: 1.272–1.780; p< 0.0001) and DAO (OR = 1.671; 95%CI: 1.201–2.325; p= 0.002) significantly increased the risk of multimorbidity. Compared to no dynapenia nor abdominal obesity, DAO was associated with significantly higher risk for arthritis and diabetes. Conclusions: DAO was significantly associated with a higher risk of incident multimorbidity, over 10 years of follow-up. The results of our study suggest that addressing DAO can potentially decrease risk for multimorbidity.
- Published
- 2023
- Full Text
- View/download PDF
38. Difference FTIR Spectroscopy of Jumping Spider Rhodopsin‑1 at 77 K.
- Author
-
Hanai, Shunpei, Nagata, Takashi, Katayama, Kota, Inukai, Shino, Koyanagi, Mitsumasa, Inoue, Keiichi, Terakita, Akihisa, and Kandori, Hideki
- Published
- 2023
- Full Text
- View/download PDF
39. Fluorescence-Based Detection of Fatty Acid β‑Oxidation in Cells and Tissues Using Quinone Methide-Releasing Probes.
- Author
-
Uchinomiya, Shohei, Nagaura, Tomoki, Weber, Mark, Matsuo, Yuya, Zenmyo, Naoki, Yoshida, Yuya, Tsuruta, Akito, Koyanagi, Satoru, Ohdo, Shigehiro, Matsunaga, Naoya, and Ojida, Akio
- Published
- 2023
- Full Text
- View/download PDF
40. The impact of urinary incontinence on multiple health outcomes: an umbrella review of meta-analysis of observational studies.
- Author
-
Soysal, Pinar, Veronese, Nicola, Ippoliti, Simona, Pizzol, Damiano, Carrie, Anne Marie, Stefanescu, Simina, López-Sánchez, Guillermo F., Barnett, Yvonne, Butler, Laurie, Koyanagi, Ai, Jacob, Louis, Ghaydya, Ramy Abou, Sheyn, David, Hijaz, Adonis K., Oliva-Lozano, Jose M., Muyor, Jose M., Trott, Mike, Kronbichler, Andreas, Grabovac, Igor, and Tully, Mark A.
- Abstract
Background and aim: We aimed to capture the breadth of health outcomes that have been associated with the presence of Urinary Incontinence (UI) and systematically assess the quality, strength, and credibility of these associations through an umbrella review and integrated meta-analyses. Methods: We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p-values, 95% prediction intervals, heterogeneity, small-study effects, and excess significance. We graded the evidence from convincing (Class I) to weak (Class IV). Results and discussion: From 3172 articles returned in search of the literature, 9 systematic reviews were included with a total of 41 outcomes. Overall, 37 out of the 41 outcomes reported nominally significant summary results (p < 0.05), with 22 associations surviving the application of a more stringent p-value (p < 10
−6 ). UI was associated with worse scores than controls in female sexual function (Class II), while it was also associated with a higher prevalence of depression (odds ratio [OR] = 1.815; 95% confidence interval [CI]: 1.551–2.124), and anxiety (OR = 1.498; 95% CI: 1.273–1.762) (Class IV). UI was associated with poorer quality of life (QoL), higher rate of mortality (hazard ratio = 2.392; 95% CI: 2.053–2.787) an increase in falls, frailty, pressure ulcers, diabetes, arthritis, and fecal incontinence (Class IV). Conclusions: UI is associated with female sexual dysfunction, with highly suggestive evidence. However, the evidence of other adverse outcomes including depression, anxiety, poorer QoL, higher mortality, falls, pressure ulcers, diabetes, arthritis, fecal incontinence, and frailty is only weak. A multidimensional approach should be taken in managing UI in the clinical setting. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
41. Effects of physical rehabilitation interventions in COVID-19 patients following discharge from hospital: A systematic review.
- Author
-
Rahmati, Masoud, Molanouri Shamsi, Mahdieh, Woo, Wongi, Koyanagi, Ai, Won Lee, Seung, Keon Yon, Dong, Shin, Jae Il, and Smith, Lee
- Published
- 2023
- Full Text
- View/download PDF
42. Food Insecurity and Substance Use Among Young Adult College Students in the United States.
- Author
-
Oh, Hans, Smith, Lee, Jacob, Louis, Du, Jinyu, Shin, Jae Il, Zhou, Sasha, and Koyanagi, Ai
- Abstract
Background: Food insecurity is prevalent among college students in the United States and has been associated with substance use. We sought to provide updated prevalence estimates and associations between food insecurity and a broad range of substances during the SARS-CoV-2 pandemic. Methods: Using cross-sectional data from the Health Minds Study (N = 94,722; September 2020–June 2021), we used multivariable logistic regression to examine associations between food insecurity and several substances, adjusting for age, gender, race/ethnicity, hours worked, and residence. We then added a block of adjustments consisting of mental health factors (depression, anxiety, loneliness, financial stress). Results: Food insecurity was associated with significantly greater odds of having used most individual substances, including greater odds of binge drinking (adjusted odds ratio [aOR], 1.21; 95% confidence interval [CI], 1.13–1.30), cigarette use (aOR, 1.91; 95% CI, 1.73–2.10), vaping (aOR, 1.74; 95% CI, 1.62–1.87), and a range of illicit or prescription drugs (using any illicit/prescription drug; aOR, 1.43; 95% CI, 1.32–1.55) These associations attenuated and many lost significance after adjusting for mental health factors. Conclusions: This study found evidence to suggest that food insecurity is related to substance use in a large sample of young adult college students in the United States, calling for targeted interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. 17-year trends of body mass index, overweight, and obesity among adolescents from 2005 to 2021, including the COVID-19 pandemic: a Korean national representative study.
- Author
-
BAN, C. Y., SHIN, H., EUM, S., YON, H., LEE, S. W., CHOI, Y. S., SHIN, Y. H., SHIN, J. U., KOYANAGI, A., JACOB, L., SMITH, L., MIN, C., YENIOVA, A. Ö., KIM, S. Y., LEE, J., YEO, S.-G., KWON, R., KOO, M. J., FOND, G., and BOYER, L.
- Abstract
OBJECTIVE: There is a lack of pediatric studies that have analyzed trends in mean body mass index (BMI) and the prevalence of obesity and overweight over a period that includes the mid-stage of the COVID-19 pandemic. Thus, we aimed to investigate trends in BMI, overweight, and obesity among Korean adolescents from 2005 to 2021, including the COVID-19 pandemic. SUBJECTS AND METHODS: We used data from the Korea Youth Risk Behavior Web-based Survey (KYRBS), which is nationally representative of South Korea. The study included middleand high-school students between the ages of 12 and 18. We examined trends in mean BMI and prevalence of obesity and/or overweight during the COVID-19 pandemic and compared these to those of pre-pandemic trends in each subgroup by gender, grade, and residential region. RESULTS: Data from 1,111,300 adolescents (mean age: 15.04 years) were analyzed. The estimated weighted mean BMI was 20.48 kg/m2 (95% CI, 20.46-20.51) between 2005 and 2007, and this was 21.61 kg/m2 (95% CI, 21.54-21.68) in 2021. The prevalence of overweight and obesity was 13.1% (95% CI, 12.9-13.3%) between 2005 and 2007 and 23.4% (95% CI, 22.8-24.0%) in 2021. The mean BMI and prevalence of obesity and overweight have gradually increased over the past 17 years; however, the extent of change in mean BMI and in the prevalence of obesity and overweight during the pandemic was distinctly less than before. The 17-year trends in the mean BMI, obesity, and overweight exhibited a considerable rise from 2005 to 2021; however, the slope during the COVID-19 pandemic (2020-2021) was significantly less prominent than in the pre-pandemic (2005-2019). CONCLUSIONS: These findings enable us to comprehend long-term trends in the mean BMI of Korean adolescents and further emphasize the need for practical prevention measures against youth obesity and overweight. [ABSTRACT FROM AUTHOR]
- Published
- 2023
44. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
- Author
-
Ong, Kanyin Liane, Stafford, Lauryn K, McLaughlin, Susan A, Boyko, Edward J, Vollset, Stein Emil, Smith, Amanda E, Dalton, Bronte E, Duprey, Joe, Cruz, Jessica A, Hagins, Hailey, Lindstedt, Paulina A, Aali, Amirali, Abate, Yohannes Habtegiorgis, Abate, Melsew Dagne, Abbasian, Mohammadreza, Abbasi-Kangevari, Zeinab, Abbasi-Kangevari, Mohsen, Abd ElHafeez, Samar, Abd-Rabu, Rami, Abdulah, Deldar Morad, Abdullah, Abu Yousuf Md, Abedi, Vida, Abidi, Hassan, Aboagye, Richard Gyan, Abolhassani, Hassan, Abu-Gharbieh, Eman, Abu-Zaid, Ahmed, Adane, Tigist Demssew, Adane, Denberu Eshetie, Addo, Isaac Yeboah, Adegboye, Oyelola A, Adekanmbi, Victor, Adepoju, Abiola Victor, Adnani, Qorinah Estiningtyas Sakilah, Afolabi, Rotimi Felix, Agarwal, Gina, Aghdam, Zahra Babaei, Agudelo-Botero, Marcela, Aguilera Arriagada, Constanza Elizabeth, Agyemang-Duah, Williams, Ahinkorah, Bright Opoku, Ahmad, Danish, Ahmad, Rizwan, Ahmad, Sajjad, Ahmad, Aqeel, Ahmadi, Ali, Ahmadi, Keivan, Ahmed, Ayman, Ahmed, Ali, Ahmed, Luai A, Ahmed, Syed Anees, Ajami, Marjan, Akinyemi, Rufus Olusola, Al Hamad, Hanadi, Al Hasan, Syed Mahfuz, AL-Ahdal, Tareq Mohammed Ali, Alalwan, Tariq A, Al-Aly, Ziyad, AlBataineh, Mohammad T, Alcalde-Rabanal, Jacqueline Elizabeth, Alemi, Sharifullah, Ali, Hassam, Alinia, Tahereh, Aljunid, Syed Mohamed, Almustanyir, Sami, Al-Raddadi, Rajaa M, Alvis-Guzman, Nelson, Amare, Firehiwot, Ameyaw, Edward Kwabena, Amiri, Sohrab, Amusa, Ganiyu Adeniyi, Andrei, Catalina Liliana, Anjana, Ranjit Mohan, Ansar, Adnan, Ansari, Golnoosh, Ansari-Moghaddam, Alireza, Anyasodor, Anayochukwu Edward, Arabloo, Jalal, Aravkin, Aleksandr Y, Areda, Demelash, Arifin, Hidayat, Arkew, Mesay, Armocida, Benedetta, Ärnlöv, Johan, Artamonov, Anton A, Arulappan, Judie, Aruleba, Raphael Taiwo, Arumugam, Ashokan, Aryan, Zahra, Asemu, Mulu Tiruneh, Asghari-Jafarabadi, Mohammad, Askari, Elaheh, Asmelash, Daniel, Astell-Burt, Thomas, Athar, Mohammad, Athari, Seyyed Shamsadin, Atout, Maha Moh'd Wahbi, Avila-Burgos, Leticia, Awaisu, Ahmed, Azadnajafabad, Sina, B, Darshan B, Babamohamadi, Hassan, Badar, Muhammad, Badawi, Alaa, Badiye, Ashish D, Baghcheghi, Nayereh, Bagheri, Nasser, Bagherieh, Sara, Bah, Sulaiman, Bahadory, Saeed, Bai, Ruhai, Baig, Atif Amin, Baltatu, Ovidiu Constantin, Baradaran, Hamid Reza, Barchitta, Martina, Bardhan, Mainak, Barengo, Noel C, Bärnighausen, Till Winfried, Barone, Mark Thomaz Ugliara, Barone-Adesi, Francesco, Barrow, Amadou, Bashiri, Hamideh, Basiru, Afisu, Basu, Sanjay, Basu, Saurav, Batiha, Abdul-Monim Mohammad, Batra, Kavita, Bayih, Mulat Tirfie, Bayileyegn, Nebiyou Simegnew, Behnoush, Amir Hossein, Bekele, Alehegn Bekele, Belete, Melaku Ashagrie, Belgaumi, Uzma Iqbal, Belo, Luis, Bennett, Derrick A, Bensenor, Isabela M, Berhe, Kidanemaryam, Berhie, Alemshet Yirga, Bhaskar, Sonu, Bhat, Ajay Nagesh, Bhatti, Jasvinder Singh, Bikbov, Boris, Bilal, Faiq, Bintoro, Bagas Suryo, Bitaraf, Saeid, Bitra, Veera R, Bjegovic-Mikanovic, Vesna, Bodolica, Virginia, Boloor, Archith, Brauer, Michael, Brazo-Sayavera, Javier, Brenner, Hermann, Butt, Zahid A, Calina, Daniela, Campos, Luciana Aparecida, Campos-Nonato, Ismael R, Cao, Yin, Cao, Chao, Car, Josip, Carvalho, Márcia, Castañeda-Orjuela, Carlos A, Catalá-López, Ferrán, Cerin, Ester, Chadwick, Joshua, Chandrasekar, Eeshwar K, Chanie, Gashaw Sisay, Charan, Jaykaran, Chattu, Vijay Kumar, Chauhan, Kirti, Cheema, Huzaifa Ahmad, Chekol Abebe, Endeshaw, Chen, Simiao, Cherbuin, Nicolas, Chichagi, Fatemeh, Chidambaram, Saravana Babu, Cho, William C S, Choudhari, Sonali Gajanan, Chowdhury, Rajiv, Chowdhury, Enayet Karim, Chu, Dinh-Toi, Chukwu, Isaac Sunday, Chung, Sheng-Chia, Coberly, Kaleb, Columbus, Alyssa, Contreras, Daniela, Cousin, Ewerton, Criqui, Michael H, Cruz-Martins, Natália, Cuschieri, Sarah, Dabo, Bashir, Dadras, Omid, Dai, Xiaochen, Damasceno, Albertino Antonio Moura, Dandona, Rakhi, Dandona, Lalit, Das, Saswati, Dascalu, Ana Maria, Dash, Nihar Ranjan, Dashti, Mohsen, Dávila-Cervantes, Claudio Alberto, De la Cruz-Góngora, Vanessa, Debele, Gebiso Roba, Delpasand, Kourosh, Demisse, Fitsum Wolde, Demissie, Getu Debalkie, Deng, Xinlei, Denova-Gutiérrez, Edgar, Deo, Salil V, Dervišević, Emina, Desai, Hardik Dineshbhai, Desale, Aragaw Tesfaw, Dessie, Anteneh Mengist, Desta, Fikreab, Dewan, Syed Masudur Rahman, Dey, Sourav, Dhama, Kuldeep, Dhimal, Meghnath, Diao, Nancy, Diaz, Daniel, Dinu, Monica, Diress, Mengistie, Djalalinia, Shirin, Doan, Linh Phuong, Dongarwar, Deepa, dos Santos Figueiredo, Francisco Winter, Duncan, Bruce B, Dutta, Siddhartha, Dziedzic, Arkadiusz Marian, Edinur, Hisham Atan, Ekholuenetale, Michael, Ekundayo, Temitope Cyrus, Elgendy, Islam Y, Elhadi, Muhammed, El-Huneidi, Waseem, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A, Endeshaw, Destaw, Esayas, Hawi Leul, Eshetu, Habitu Birhan, Etaee, Farshid, Fadhil, Ibtihal, Fagbamigbe, Adeniyi Francis, Fahim, Ayesha, Falahi, Shahab, Faris, MoezAlIslam Ezzat Mahmoud, Farrokhpour, Hossein, Farzadfar, Farshad, Fatehizadeh, Ali, Fazli, Ghazal, Feng, Xiaoqi, Ferede, Tomas Y, Fischer, Florian, Flood, David, Forouhari, Ali, Foroumadi, Roham, Foroutan Koudehi, Masoumeh, Gaidhane, Abhay Motiramji, Gaihre, Santosh, Gaipov, Abduzhappar, Galali, Yaseen, Ganesan, Balasankar, Garcia-Gordillo, MA, Gautam, Rupesh K, Gebrehiwot, Mesfin, Gebrekidan, Kahsu Gebrekirstos, Gebremeskel, Teferi Gebru, Getacher, Lemma, Ghadirian, Fataneh, Ghamari, Seyyed-Hadi, Ghasemi Nour, Mohammad, Ghassemi, Fariba, Golechha, Mahaveer, Goleij, Pouya, Golinelli, Davide, Gopalani, Sameer Vali, Guadie, Habtamu Alganeh, Guan, Shi-Yang, Gudayu, Temesgen Worku, Guimarães, Rafael Alves, Guled, Rashid Abdi, Gupta, Rajeev, Gupta, Kartik, Gupta, Veer Bala, Gupta, Vivek Kumar, Gyawali, Bishal, Haddadi, Rasool, Hadi, Najah R, Haile, Teklehaimanot Gereziher, Hajibeygi, Ramtin, Haj-Mirzaian, Arvin, Halwani, Rabih, Hamidi, Samer, Hankey, Graeme J, Hannan, Md Abdul, Haque, Shafiul, Harandi, Hamid, Harlianto, Netanja I, Hasan, S M Mahmudul, Hasan, Syed Shahzad, Hasani, Hamidreza, Hassanipour, Soheil, Hassen, Mohammed Bheser, Haubold, Johannes, Hayat, Khezar, Heidari, Golnaz, Heidari, Mohammad, Hessami, Kamran, Hiraike, Yuta, Holla, Ramesh, Hossain, Sahadat, Hossain, Md Shakhaoat, Hosseini, Mohammad-Salar, Hosseinzadeh, Mehdi, Hosseinzadeh, Hassan, Huang, Junjie, Huda, Md Nazmul, Hussain, Salman, Huynh, Hong-Han, Hwang, Bing-Fang, Ibitoye, Segun Emmanuel, Ikeda, Nayu, Ilic, Irena M, Ilic, Milena D, Inbaraj, Leeberk Raja, Iqbal, Afrin, Islam, Sheikh Mohammed Shariful, Islam, Rakibul M, Ismail, Nahlah Elkudssiah, Iso, Hiroyasu, Isola, Gaetano, Itumalla, Ramaiah, Iwagami, Masao, Iwu, Chidozie C D, Iyamu, Ihoghosa Osamuyi, Iyasu, Assefa N, Jacob, Louis, Jafarzadeh, Abdollah, Jahrami, Haitham, Jain, Rajesh, Jaja, Chinwe, Jamalpoor, Zahra, Jamshidi, Elham, Janakiraman, Balamurugan, Jayanna, Krishnamurthy, Jayapal, Sathish Kumar, Jayaram, Shubha, Jayawardena, Ranil, Jebai, Rime, Jeong, Wonjeong, Jin, Yinzi, Jokar, Mohammad, Jonas, Jost B, Joseph, Nitin, Joseph, Abel, Joshua, Charity Ehimwenma, Joukar, Farahnaz, Jozwiak, Jacek Jerzy, Kaambwa, Billingsley, Kabir, Ali, Kabthymer, Robel Hussen, Kadashetti, Vidya, Kahe, Farima, Kalhor, Rohollah, Kandel, Himal, Karanth, Shama D, Karaye, Ibraheem M, Karkhah, Samad, Katoto, Patrick DMC, Kaur, Navjot, Kazemian, Sina, Kebede, Sewnet Adem, Khader, Yousef Saleh, Khajuria, Himanshu, Khalaji, Amirmohammad, Khan, Moien AB, Khan, Maseer, Khan, Ajmal, Khanal, Saval, Khatatbeh, Moawiah Mohammad, Khater, Amir M, Khateri, Sorour, khorashadizadeh, Fatemeh, Khubchandani, Jagdish, Kibret, Biruk Getahun, Kim, Min Seo, Kimokoti, Ruth W, Kisa, Adnan, Kivimäki, Mika, Kolahi, Ali-Asghar, Komaki, Somayeh, Kompani, Farzad, Koohestani, Hamid Reza, Korzh, Oleksii, Kostev, Karel, Kothari, Nikhil, Koyanagi, Ai, Krishan, Kewal, Krishnamoorthy, Yuvaraj, Kuate Defo, Barthelemy, Kuddus, Mohammed, Kuddus, Md Abdul, Kumar, Rakesh, Kumar, Harish, Kundu, Satyajit, Kurniasari, Maria Dyah, Kuttikkattu, Ambily, La Vecchia, Carlo, Lallukka, Tea, Larijani, Bagher, Larsson, Anders O, Latief, Kamaluddin, Lawal, Basira Kankia, Le, Thao Thi Thu, Le, Trang Thi Bich, Lee, Shaun Wen Huey, Lee, Munjae, Lee, Wei-Chen, Lee, Paul H, Lee, Sang-woong, Lee, Seung Won, Legesse, Samson Mideksa, Lenzi, Jacopo, Li, Yongze, Li, Ming-Chieh, Lim, Stephen S, Lim, Lee-Ling, Liu, Xuefeng, Liu, Chaojie, Lo, Chun-Han, Lopes, Graciliana, Lorkowski, Stefan, Lozano, Rafael, Lucchetti, Giancarlo, Maghazachi, Azzam A, Mahasha, Phetole Walter, Mahjoub, Soleiman, Mahmoud, Mansour Adam, Mahmoudi, Razzagh, Mahmoudimanesh, Marzieh, Mai, Anh Tuan, Majeed, Azeem, Majma Sanaye, Pantea, Makris, Konstantinos Christos, Malhotra, Kashish, Malik, Ahmad Azam, Malik, Iram, Mallhi, Tauqeer Hussain, Malta, Deborah Carvalho, Mamun, Abdullah A, Mansouri, Borhan, Marateb, Hamid Reza, Mardi, Parham, Martini, Santi, Martorell, Miquel, Marzo, Roy Rillera, Masoudi, Reza, Masoudi, Sahar, Mathews, Elezebeth, Maugeri, Andrea, Mazzaglia, Giampiero, Mekonnen, Teferi, Meshkat, Mahboobeh, Mestrovic, Tomislav, Miao Jonasson, Junmei, Miazgowski, Tomasz, Michalek, Irmina Maria, Minh, Le Huu Nhat, Mini, GK, Miranda, J Jaime, Mirfakhraie, Reza, Mirrakhimov, Erkin M, Mirza-Aghazadeh-Attari, Mohammad, Misganaw, Awoke, Misgina, Kebede Haile, Mishra, Manish, Moazen, Babak, Mohamed, Nouh Saad, Mohammadi, Esmaeil, Mohammadi, Mohsen, Mohammadian-Hafshejani, Abdollah, Mohammadshahi, Marita, Mohseni, Alireza, Mojiri-forushani, Hoda, Mokdad, Ali H, Momtazmanesh, Sara, Monasta, Lorenzo, Moniruzzaman, Md, Mons, Ute, Montazeri, Fateme, Moodi Ghalibaf, AmirAli, Moradi, Yousef, Moradi, Maryam, Moradi Sarabi, Mostafa, Morovatdar, Negar, Morrison, Shane Douglas, Morze, Jakub, Mossialos, Elias, Mostafavi, Ebrahim, Mueller, Ulrich Otto, Mulita, Francesk, Mulita, Admir, Murillo-Zamora, Efrén, Musa, Kamarul Imran, Mwita, Julius C, Nagaraju, Shankar Prasad, Naghavi, Mohsen, Nainu, Firzan, Nair, Tapas Sadasivan, Najmuldeen, Hastyar Hama Rashid, Nangia, Vinay, Nargus, Shumaila, Naser, Abdallah Y, Nassereldine, Hasan, Natto, Zuhair S, Nauman, Javaid, Nayak, Biswa Prakash, Ndejjo, Rawlance, Negash, Hadush, Negoi, Ruxandra Irina, Nguyen, Hau Thi Hien, Nguyen, Dang H, Nguyen, Phat Tuan, Nguyen, Van Thanh, Nguyen, Hien Quang, Niazi, Robina Khan, Nigatu, Yeshambel T, Ningrum, Dina Nur Anggraini, Nizam, Muhammad A, Nnyanzi, Lawrence Achilles, Noreen, Mamoona, Noubiap, Jean Jacques, Nzoputam, Ogochukwu Janet, Nzoputam, Chimezie Igwegbe, Oancea, Bogdan, Odogwu, Nkechi Martina, Odukoya, Oluwakemi Ololade, Ojha, Vivek Anand, Okati-Aliabad, Hassan, Okekunle, Akinkunmi Paul, Okonji, Osaretin Christabel, Okwute, Patrick Godwin, Olufadewa, Isaac Iyinoluwa, Onwujekwe, Obinna E, Ordak, Michal, Ortiz, Alberto, Osuagwu, Uchechukwu Levi, Oulhaj, Abderrahim, Owolabi, Mayowa O, Padron-Monedero, Alicia, Padubidri, Jagadish Rao, Palladino, Raffaele, Panagiotakos, Demosthenes, Panda-Jonas, Songhomitra, Pandey, Ashok, Pandey, Anamika, Pandi-Perumal, Seithikurippu R, Pantea Stoian, Anca Mihaela, Pardhan, Shahina, Parekh, Tarang, Parekh, Utsav, Pasovic, Maja, Patel, Jay, Patel, Jenil R, Paudel, Uttam, Pepito, Veincent Christian Filipino, Pereira, Marcos, Perico, Norberto, Perna, Simone, Petcu, Ionela-Roxana, Petermann-Rocha, Fanny Emily, Podder, Vivek, Postma, Maarten J, Pourali, Ghazaleh, Pourtaheri, Naeimeh, Prates, Elton Junio Sady, Qadir, Mirza Muhammad Fahd, Qattea, Ibrahim, Raee, Pourya, Rafique, Ibrar, Rahimi, Mehran, Rahimifard, Mahban, Rahimi-Movaghar, Vafa, Rahman, Md Obaidur, Rahman, Muhammad Aziz, Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rahman, Md Mosfequr, Rahmani, Mohamed, Rahmani, Shayan, Rahmanian, Vahid, Rahmawaty, Setyaningrum, Rahnavard, Niloufar, Rajbhandari, Bibek, Ram, Pradhum, Ramazanu, Sheena, Rana, Juwel, Rancic, Nemanja, Ranjha, Muhammad Modassar Ali Nawaz, Rao, Chythra R, Rapaka, Deepthi, Rasali, Drona Prakash, Rashedi, Sina, Rashedi, Vahid, Rashid, Ahmed Mustafa, Rashidi, Mohammad-Mahdi, Ratan, Zubair Ahmed, Rawaf, Salman, Rawal, Lal, Redwan, Elrashdy Moustafa Mohamed, Remuzzi, Giuseppe, Rengasamy, Kannan RR, Renzaho, Andre M N, Reyes, Luis Felipe, Rezaei, Nima, Rezaei, Nazila, Rezaeian, Mohsen, Rezazadeh, Hossein, Riahi, Seyed Mohammad, Rias, Yohanes Andy, Riaz, Muhammad, Ribeiro, Daniela, Rodrigues, Mónica, Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Rohloff, Peter, Roshandel, Gholamreza, Roustazadeh, Abazar, Rwegerera, Godfrey M, Saad, Aly M A, Saber-Ayad, Maha Mohamed, Sabour, Siamak, Sabzmakan, Leila, Saddik, Basema, Sadeghi, Erfan, Saeed, Umar, Saeedi Moghaddam, Sahar, Safi, Sare, Safi, Sher Zaman, Saghazadeh, Amene, Saheb Sharif-Askari, Narjes, Saheb Sharif-Askari, Fatemeh, Sahebkar, Amirhossein, Sahoo, Soumya Swaroop, Sahoo, Harihar, Saif-Ur-Rahman, KM, Sajid, Mirza Rizwan, Salahi, Sarvenaz, Salahi, Saina, Saleh, Mohamed A, Salehi, Mohammad Amin, Salomon, Joshua A, Sanabria, Juan, Sanjeev, Rama Krishna, Sanmarchi, Francesco, Santric-Milicevic, Milena M, Sarasmita, Made Ary, Sargazi, Saman, Sathian, Brijesh, Sathish, Thirunavukkarasu, Sawhney, Monika, Schlaich, Markus P, Schmidt, Maria Inês, Schuermans, Art, Seidu, Abdul-Aziz, Senthil Kumar, Nachimuthu, Sepanlou, Sadaf G, Sethi, Yashendra, Seylani, Allen, Shabany, Maryam, Shafaghat, Tahereh, Shafeghat, Melika, Shafie, Mahan, Shah, Nilay S, Shahid, Samiah, Shaikh, Masood Ali, Shanawaz, Mohd, Shannawaz, Mohammed, Sharfaei, Sadaf, Shashamo, Bereket Beyene, Shiri, Rahman, Shittu, Aminu, Shivakumar, K M, Shivalli, Siddharudha, Shobeiri, Parnian, Shokri, Fereshteh, Shuval, Kerem, Sibhat, Migbar Mekonnen, Silva, Luís Manuel Lopes Rodrigues, Simpson, Colin R, Singh, Jasvinder A, Singh, Paramdeep, Singh, Surjit, Siraj, Md Shahjahan, Skryabina, Anna Aleksandrovna, Sohag, Abdullah Al Mamun, Soleimani, Hamidreza, Solikhah, Solikhah, Soltani-Zangbar, Mohammad Sadegh, Somayaji, Ranjani, Sorensen, Reed J D, Starodubova, Antonina V, Sujata, Sujata, Suleman, Muhammad, Sun, Jing, Sundström, Johan, Tabarés-Seisdedos, Rafael, Tabatabaei, Seyyed Mohammad, Tabatabaeizadeh, Seyed-Amir, Tabish, Mohammad, Taheri, Majid, Taheri, Ensiyeh, Taki, Elahe, Tamuzi, Jacques JL Lukenze, Tan, Ker-Kan, Tat, Nathan Y, Taye, Birhan Tsegaw, Temesgen, Worku Animaw, Temsah, Mohamad-Hani, Tesler, Riki, Thangaraju, Pugazhenthan, Thankappan, Kavumpurathu Raman, Thapa, Rajshree, Tharwat, Samar, Thomas, Nihal, Ticoalu, Jansje Henny Vera, Tiyuri, Amir, Tonelli, Marcello, Tovani-Palone, Marcos Roberto, Trico, Domenico, Trihandini, Indang, Tripathy, Jaya Prasad, Tromans, Samuel Joseph, Tsegay, Guesh Mebrahtom, Tualeka, Abdul Rohim, Tufa, Derara Girma, Tyrovolas, Stefanos, Ullah, Sana, Upadhyay, Era, Vahabi, Seyed Mohammad, Vaithinathan, Asokan Govindaraj, Valizadeh, Rohollah, van Daalen, Kim Robin, Vart, Priya, Varthya, Shoban Babu, Vasankari, Tommi Juhani, Vaziri, Siavash, Verma, Madhur verma, Verras, Georgios-Ioannis, Vo, Danh Cao, Wagaye, Birhanu, Waheed, Yasir, Wang, Ziyue, Wang, Yanqing, Wang, Cong, Wang, Fang, Wassie, Gizachew Tadesse, Wei, Melissa Y Wei, Weldemariam, Abrha Hailay, Westerman, Ronny, Wickramasinghe, Nuwan Darshana, Wu, YiFan, Wulandari, Ratna DWI, Xia, Juan, Xiao, Hong, Xu, Suowen, Xu, Xiaoyue, Yada, Dereje Y, Yang, Lin, Yatsuya, Hiroshi, Yesiltepe, Metin, Yi, Siyan, Yohannis, Hunachew Kibret, Yonemoto, Naohiro, You, Yuyi, Zaman, Sojib Bin, Zamora, Nelson, Zare, Iman, Zarea, Kourosh, Zarrintan, Armin, Zastrozhin, Mikhail Sergeevich, Zeru, Naod Gebrekrstos, Zhang, Zhi-Jiang, Zhong, Chenwen, Zhou, Jingjing, Zielińska, Magdalena, Zikarg, Yossef Teshome, Zodpey, Sanjay, Zoladl, Mohammad, Zou, Zhiyong, Zumla, Alimuddin, Zuniga, Yves Miel H, Magliano, Dianna J, Murray, Christopher J L, Hay, Simon I, and Vos, Theo
- Abstract
Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050.
- Published
- 2023
- Full Text
- View/download PDF
45. Lock-in thermographic measurement and model-based evaluation of effective thermal diffusivity to quantify early stage fatigue damage of CFRP
- Author
-
Avdelidis, Nicolas P., Fujita, Ryohei, Kudo, Natsuko, Abe, Shun, Fikry, M. J. Mohammad, Koyanagi, Jun, Ogihara, Shinji, and Nagano, Hosei
- Published
- 2023
- Full Text
- View/download PDF
46. Treatment outcomes of lobectomy with and without mediastinal lymph node dissection in older patients with clinical N0 non-small cell lung cancer
- Author
-
Fujita, Tomohiro, Koyanagi, Akira, and Kishimoto, Koji
- Abstract
Background To reduce surgical stress, we omit mediastinal lymph node dissection (MLND) in patients with non-small cell lung cancer aged ≥80 years without N1 metastasis, as confirmed via surgery. This study examined the effect of MLND omission on prognosis.Methods Altogether, 212 eligible patients with clinical N0 non-small cell lung cancer underwent video-assisted thoracoscopic lobectomy between 2007 and 2017. Patients were classified into two groups as follows: patients aged 75–79 years who underwent MLND group, and patients aged ≥80 years in whom MLND was omitted (non-MLND group). Propensity score matching was performed between the two groups.Results There were 86 patients after matching. The non-MLND group showed shorter operative time (237.5 min vs. 207.5 min, p= 0.018). No differences in postoperative complications were noted between the two groups. Between the MLND group and non-MLND group, the 5-year overall survival rates were 84.0% and 84.7% (p= 0.989), relapse-free survival rates were 69.8% and 74.7% (p= 0.855), and cancer-specific survival rates were 91.4% and 91.6% (p= 0.700), respectively. These results did not differ significantly.Conclusion This study demonstrated that MLND does not affect the prognosis of patients with non-small cell lung cancer aged ≥80 years. Lobectomy without MLND is one of the surgical treatment options in older patients with clinical N0 non-small cell lung cancer. Naturally, the clinical stage of patients must be carefully evaluated before surgery.
- Published
- 2023
- Full Text
- View/download PDF
47. Cerebral venous thrombosis after ChAdOx1 nCoV-19 vaccination: a systematic review.
- Author
-
SONG, T.-J., SHIN, J. I., YON, D. K., LEE, S. W., HWANG, S. Y., HWANG, J., PARK, S. H., LEE, S. B., LEE, M. H., KIM, M. S., KOYANAGI, A., TIZAOUI, K., KIM, J. H., and SMITH, L.
- Abstract
OBJECTIVE: To perform a systematic review of case reports or case series regarding thrombosis with thrombocytopenia syndrome (TTS) and cerebral venous thrombosis (CVT) related to ChAdOx1 nCoV-19 vaccination to address the clinical features, laboratory findings, treatment modalities, and prognosis related with CVT. SUBJECTS AND METHODS: We included 64 TTS patients from 19 articles, 6 case series and 13 case reports, in which thrombosis occurred after the first dose of ChAdOx1 nCoV-19 vaccination published up to 30 June 2021 in Embase, ePubs, Medline/PubMed, Scopus, and Web of Science databases. RESULTS: Of the 64 TTS patients, 38 (59.3%) had CVT. Patients with CVT were younger (median 36.5 vs. 52.5 years, p<0.001), had lower fibrinogen levels (130 vs. 245 mg/dL, p=0.008), had more frequent history of intracerebral hemorrhage (ICH), and had higher mortality rate (48.6% vs. 19.2%, p=0.020) than that of patients without CVT. In multivariable analysis, the possibility of presence of CVT was higher in younger age groups [odd ratio (OR): 0.91, 95% confidence interval (CI): (0.86-0.97, p<0.001)] and those with accompanying intracerebral hemorrhage (ICH) (OR: 13.60, 95% CI (1.28-144.12, p=0.045). CONCLUSIONS: Our study demonstrated that CVT related to ChAdOx1 nCoV-19 vaccination was associated with younger age, low levels of fibrinogen, presence of ICH and more frequent mortality compared to those of non-CVT. If TTS occurs after ChAdOx1 nCoV-19 vaccination, the presence of CVT in patients with young age or ICH should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2023
48. Ischemic complications in the neurosurgical and endovascular treatments of craniocervical junction arteriovenous fistulas: a multicenter study.
- Author
-
Takai, Keisuke, Endo, Toshiki, Seki, Toshitaka, Inoue, Tomoo, Koyanagi, Izumi, and Mitsuhara, Takafumi
- Published
- 2022
- Full Text
- View/download PDF
49. Association between sarcopenia and quality of life among adults aged ≥ 65 years from low- and middle-income countries.
- Author
-
Smith, Lee, Sánchez, Guillermo F. López, Veronese, Nicola, Soysal, Pinar, Kostev, Karel, Jacob, Louis, Oh, Hans, Tully, Mark A., Butler, Laurie, Parsa, Ali Davod, Hwang, Soo Young, Shin, Jae Il, and Koyanagi, Ai
- Abstract
Background: Sarcopenia has been associated with a lower quality of life (QoL). However, studies on this association from low- and middle-income countries (LMICs) are scarce. Aims: To examine the association between sarcopenia and QoL, in a large nationally representative sample of older adults from six LMICs. Methods: Cross-sectional, community-based data from the WHO study on global ageing and adult health (SAGE) were analysed. Non-severe sarcopenia was defined as having low skeletal muscle mass (SMM) and weak handgrip strength but no slow gait speed, while severe sarcopenia was defined as having low SMM, weak handgrip strength, and slow gait speed. QoL was assessed with the 8-item WHO QoL instrument (range 0–100) with higher scores representing better QoL. Multivariable linear regression analysis was conducted. Results: Data on 14,585 people aged ≥ 65 years were analyzed [mean (SD) age 72.6 (11.5) years; 55.0% female]. After adjustment for potential confounders, compared to no sarcopenia, severe sarcopenia was associated with a significant − 3.37 points [95% CI − 5.56, − 1.18] lower QoL score. Non-severe sarcopenia was not significantly associated with lower QoL. Discussion: The association between sarcopenia and QoL observed in our study may be explained by factors such as functional impairment and disability related with sarcopenia. Conclusions: In this large representative sample of older adults from multiple LMICs, compared to no sarcopenia, only severe sarcopenia was associated with a significantly lower QoL score. Interventions to prevent or manage sarcopenia among older adults in LMICs may contribute to better QoL in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Comorbid health conditions in people with attention-deficit/hyperactivity disorders: An umbrella review of systematic reviews and meta-analyses.
- Author
-
Kang, Jiseung, Lee, Hyeri, Kim, Soeun, Kim, Hyeon Jin, Lee, Hayeon, Kwon, Rosie, Son, Yejun, Kim, Sunyoung, Woo, Ho Geol, Kim, Min Seo, Koyanagi, Ai, Smith, Lee, Fond, Guillaume, Boyer, Laurent, Rahmati, Masoud, López Sánchez, Guillermo F., Dragioti, Elena, Solmi, Marco, Shin, Jae Il, and Kim, Tae
- Abstract
We aimed to systematically review meta-analyses on the link between attention-deficit/hyperactivity disorder (ADHD) and a broad range of psychiatric, physical, and behavioral health conditions (PROSPERO; no.CRD42023448907). We identified 22 meta-analyses that included 544 primary studies, covering 76 unique conditions in over 234 million participants across 36 countries and six continents. We found high-certainty evidence for the associations between ADHD and neuropsychiatric conditions (bipolar disorders, personality disorders, schizophrenia, and pragmatic language skills), night awakenings, obesity, decayed incipient surfaces, asthma, astigmatism, hyperopia and hypermetropia, strabismus, and suicide ideation. Moderate-certainty evidence suggested that ADHD was associated with headache, mood/affective disorders, depression, bruxism, bone fractures, atopic rhinitis, vision problems, suicide attempts, completed suicide, and all-cause mortality. Low-certainty evidence indicated associations with eating disorders, sleep efficiency, type 2 diabetes, dental trauma prevalence, atopic diseases, and atopic dermatitis. Very low-certainty evidence showed associations between ADHD and several sleep parameters. We found varied levels of evidence for the associations of ADHD with multiple health conditions. Therefore, clinicians should consider a wide range of neurological, psychiatric, sleep and suicide-related, metabolic, musculoskeletal, oral, allergic, and visual conditions, as well as the increased risk of mortality when assessing individuals with ADHD. [Display omitted] • A comprehensive review of 22 meta-analyses covering 76 unique health outcomes linked with ADHD was conducted. • These include neurological, psychiatric, behavioral, metabolic, musculoskeletal, oral, allergic, visual conditions, and mortality. • These associations had evidence ranging from very low to high certainty. • The associations between ADHD and several health outcomes necessitate a more comprehensive approach to managing ADHD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.